A retrospective analysis of a community based weight loss programme in conjunction with group behavioural change sessions in women with polycystic ovary syndrome (PCOS). by Nikokavoura, Efsevia Anastasia
  
 
OpenAIR@RGU 
 
The Open Access Institutional Repository 
at Robert Gordon University 
 
http://openair.rgu.ac.uk 
 
 
Citation Details 
 
Citation for the version of the work held in ‘OpenAIR@RGU’: 
 
NIKOKAVOURA, E. A., 2014. A retrospective analysis of a 
community based weight loss programme in conjunction with 
group behavioural change sessions in women with polycystic 
ovary syndrome (PCOS). Available from OpenAIR@RGU. [online]. 
Available from: http://openair.rgu.ac.uk 
 
 
 
 
 
 
 
Copyright 
Items in ‘OpenAIR@RGU’, Robert Gordon University Open Access Institutional Repository, 
are protected by copyright and intellectual property law. If you believe that any material 
held in ‘OpenAIR@RGU’ infringes copyright, please contact openair-help@rgu.ac.uk with 
details. The item will be removed from the repository while the claim is investigated. 
  
 
 
 
 
A Retrospective Analysis Of A Community Based Weight Loss 
Programme In Conjunction With Group Behavioural Change 
Sessions In Women With Polycystic Ovary Syndrome (PCOS)  
 
 
 
Efsevia Anastasia Nikokavoura 
 
 
 
 
 
 
A thesis submitted in partial fulfilment of the  
requirements of the  
Robert Gordon University  
for the degree of Master of Research 
 
 
 
 
 
 
 
 
 
 
 
 
Centre for Obesity Research and Epidemiology, CORE 
Institute for Health and Welfare Research, IHWR  
Robert Gordon University 
Aberdeen, UK 
November 2014 
2 
 
 
PERSONAL CONTACT DETAILS 
 
Mrs Efsevia Anastasia Nikokavoura 
E-mail: 0817136@rgu.ac.uk /enicokavoura@yahoo.com 
Phone number: +44 (0) 1224 262843  
Institute for Health and Welfare Research (IHWR) 
Centre for Obesity Research and Epidemiology (CORE)  
Robert Gordon University  
Riverside East 
Garthdee Road 
Aberdeen 
AB10 7GJ 
 
 
 
 
 
 
 
 
 
 
 
 
 
3 
 
SUPERVISOR’S CONTACT DETAILS 
 
Principal Supervisor:  
Dr Wendy Wrieden, Reader 
E-mail: w.wrieden@rgu.ac.uk 
Phone number: (+) 44 (0) 1224 262856  
Institute for Health and Welfare Research (IHWR) 
School of Pharmacy and Life Sciences 
Robert Gordon University 
Riverside East 
Garthdee Road 
Aberdeen 
AB10 7GJ 
 
Secondary Supervisor: Professor Iain Broom 
E-mail: j.broom@rgu.ac.uk 
Phone number: +44 (0) 1224 262895 
Institute for Health and Welfare Research (IHWR) 
Centre for Obesity Research and Epidemiology (CORE) 
Robert Gordon University  
Riverside East 
Garthdee Road 
Aberdeen 
AB10 7GJ 
4 
 
Third Supervisor: 
Dr. Catherine Rolland, Lecturer 
E-mail: ext.rolland1@rgu.ac.uk 
Phone number: +44 (0) 1224 262893 
Institute for Health and Welfare Research (IHWR) 
Centre for Obesity Research and Epidemiology (CORE) 
Robert Gordon University  
Riverside East 
Garthdee Road 
Aberdeen 
AB10 7GJ 
 
Fourth supervisor: Dr John G Love  
E-mail: j.g.love@rgu.ac.uk 
Phone number: (+) 44 (0) 1224 263228  
Institute for Health and Welfare Research (IHWR) 
School of Applied Social Studies 
Faculty of Health & Social Care 
Robert Gordon University 
Garthdee Road 
Aberdeen 
AB10 7QG 
 
5 
 
Abstract 
 
Polycystic Ovary Syndrome (PCOS) is variously reported to affect between 5-26 
% of reproductive age women in the UK and it accounts for up to to 75% of 
women attending fertility clinics due to anovulation. The major symptoms 
include ovarian disruption, hyperandrogenism, insulin resistance and polycystic 
ovaries. Interestingly, at least half of the women with PCOS are obese, with the 
excess weight playing a pathogenic role in the development and/or progress of 
the syndrome. In addition, PCOS is associated with negative psycho-social 
symptoms and overall a poorer quality of life. 
 
Despite the increasing prevalence of PCOS, there is still a lack of consensus over 
the diagnostic criteria and large scale, well planned trials are limited. The first-
line treatment option for overweight/obese women with PCOS is diet and 
lifestyle interventions, however optimal dietary guidelines are missing. Although 
a number of different dietary approaches have been investigated, data on the 
efficacy of very low calorie diets (VLCDs) on PCOS, are still lacking and further 
investigations both in the short and longer term data are needed. 
 
The aim of this project is to investigate how overweight/obese women with 
PCOS respond to a commercial VLCD in conjunction with group behavioural 
change sessions, as compared to overweight/obese women without PCOS. 
Weight loss was achieved via a VLCD with an average intake of 630 kcal (57g 
protein, 57 g carbohydrate, 18g fat , 16g fibre and ≥100% recommended daily 
allowances (RDA) for vitamins and minerals). Data from women recruited into 
LighterLife Total from 2006 to 2011, were analysed at baseline, 12 weeks and 1 
year.  
 
The baseline analysis from the overweight/obese female participants, revealed 
significant differences in anthropometric parameters between women with and 
without PCOS. Women with PCOS were younger (mean ±SD) (34.5 ±8.2 versus 
41.8±11.3, p<0.001), had greater body weight (105.7±19.3 versus 97.8±17.0, 
p<0.001), BMI (39.01±6.6 versus 36.4±5.8, p<0.001 and waist circumference 
(115.9±15.0 versus 109.9±12.9, p<0.001). A subset of these participants was 
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matched for age and BMI, and their analysis showed no significant differences at 
weight change at 12 weeks and 1 year. In more detail, a completers analysis 
after 12 weeks of VLCD, showed that the total weight change did not differ 
significantly between the PCOS group (n=137) and the non-PCOS group 
(n=137)  (-10.4kg ±10.6 versus -10.4 kg ± 10.4, p=0.938) and the percentage 
of weight loss achieved by PCOS women was 17.1% ±5.6 versus 18.2% ±4.4 by 
the non PCOS group (p=0.08). Also, there were no differences after 1 year in 
weight (94.2 ± 19.9, n=41, versus 90.3 ± 27.6, n=35,p=0.476) and in BMI 
(33.4 ± 8.5, n=41, versus 35.2 ± 7.6, n=35, p=0.476). Moreover, the 
percentage of weight loss achieved by PCOS women at 1 year was similar with 
the one achieved by the non PCOS women (-15.6%±15.6 versus -12.4% ± 
13.3, p=0.35). 
 
Overall, it appears that this commercial VLCD alongside behavioural therapy, can 
be an effective strategy for achieving weight reduction in cases of excess weight 
in women with PCOS.  However, further investigations are needed to achieve a 
thorough way of understanding the physiology of weight loss in PCOS via a VLCD 
approach.  
 
Keywords: Polycystic ovary syndrome (PCOS), very low calorie diet (VLCD), 
lifestyle, weight, fertility, women, behavioural, obesity 
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Introduction 
 
1.2 Identification, diagnosis and prevalence of PCOS 
 
In 1721, an Italian medical scientist , Antonio Vallisneri, gave for the first time a 
description of women who presented features of polycystic ovary syndrome 
(PCOS): “Young peasant woman, married, moderately plump, infertile, with 
ovaries larger than normal, like doves' eggs, lumpy, shiny and whitish” (Cooke, 
1989). Then, in 1935, Stein and Leventhal were the first to investigate the 
association between bilateral polycystic ovaries and amenorrhea, infertility, 
hirsutism, acne and obesity and classify the cluster of all these symptoms as a 
syndrome (Stein 1935). Thus for many years, the combination of the above 
clinical features, was referred to as the “Stein-Leventhal syndrome”. It is 
interesting to note that excess weight was part of the syndrome, since its first 
description. 
 
Nowadays, PCOS is one of the most common female endocrine disorders, 
affecting 5- 26% of women of reproductive age (12-45 years old) in the United 
Kingdom (Michelmore et al. 1999, Hopkinson et al. 1998). This great variability 
observed is due to several factors. Firstly, its diagnosis is based on ultrasound 
and/or blood tests and as this can be quite costly, research investigating the 
prevalence of this syndrome is based on convenience samples, that are less than 
400 individuals (March et al. 2010). Secondly, its diagnosis is mainly a 
“diagnosis of exclusion”, implying that other causes of androgen excess or 
ovulatory disorders with well defined aetiologies are excluded, e.g. Cushing’s 
syndrome, ovarian tumours, adrenal hyperplasia, thyroid dysfunction. There is, 
however, a lack of consensus over the diagnostic criteria used by physicians as 
well as a lack of robust methodology in the PCOS research, resulting in the large 
variability of the reported prevalence.  
 
The most commonly used criteria are briefly described in Table 1: 
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Table 1: The different diagnostic criteria of PCOS 
 
 
Interestingly, by using the NIH criteria (Zawadzki and Dunaif 1992), the world 
prevalence of PCOS in reproductive age, ranges from 5 to 12% whereas the 
prevalence would double or triple if the Rotterdam criteria (2004) were used. 
This happens due to the fact that by the use of the latter criteria, 2 new 
phenotypes are being created: (1) Women with polycystic ovaries and ovulatory 
dysfunction but without androgen excess and (2) Women with polycystic ovaries 
and androgen excess, but with no ovulatory dysfunction.  
 
Additionally, the prevalence as well as the expression of the PCOS 
symptomatology may differ according to patient’s ethnicity. For instance, it has 
been suggested that PCOS is more prevalent in women of South Asian origin, 
than in Caucasians. However, research on the prevalence of PCOS in different 
Diagnostic Criteria Criteria applied 
The European definition (Adams, Franks 
et al. 1985) 
 
(i) Polycystic ovaries identified by ultrasound plus (ii) 
Menstrual disturbance and/or signs of hyperandrogenism 
The American definition of 1990 by the 
National Institutes of Health (NIH, 
(Zawadzki, Dunaif 1992) 
 
(i)Clinical and/or biochemical signs of hyperandrogenism plus 
(ii) Oligo-ovulation or anovulation plus (iii) Exclusion of related 
disorders 
The bridge between the European and 
the US definition (Homburg 2002) 
Women with at least one of the following should undergo 
ovarian sonography: Hirsutism, acne, menstrual disturbance, 
anovulatory infertility. Then, if sonography depicts polycystic 
ovarian morphology, PCOS is confirmed. If not, further 
biochemical tests are needed (e.g. LH, TT, FSH, insulin 
homeostasis and glucose tolerance) and if any of them is 
abnormal, then PCOS is diagnosed. 
The Rotterdam criteria (Rotterdam 
ESHRE/ASRM-Sponsored PCOS 
Consensus Workshop Group 2004) 
PCOS diagnosis implies the existence of at least two of the 
following, in addition to the exclusion of related disorders: 
(i)Oligo-ovulation or anovulation, (ii)clinical and/or 
biochemical signs of hyperandrogenism, (iii) polycystic ovaries 
The modified NIH criteria (Azziz 2005) PCOS patients should have all of the following: (i)Clinical 
and/or biochemical signs of hyperandrogenism, (ii)ovarian 
dysfunction: oligo-ovulation or anovulation and/or polycystic 
ovarian morphology,(iii) exclusion of relative disorders 
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ethnic groups is limited and the results can be conflicting as some reviews 
suggest that the expression of PCOS is different among different ethnicities and 
not the prevalence of PCOS (Crosignani and Nicolosi 2001). Thusthere is a need 
for further studies to be conducted in large populations using the same criteria.  
 
1.2 Investigation of the Aetiology of PCOS  
 
PCOS is said to be responsible for up to 75% of cases of infertility caused by 
anovulation among women who attend infertility clinics in the UK (Franks 1989, 
Franks 1995). However, the exact aetiology and pathophysiology of PCOS is 
complicated. The hormonal imbalance due to a combination of elevated 
androgen levels and increased insulin secretion in combination with 
environmental e.g. lifestyle and genetic factors contribute to the aetiology of this 
syndrome. The most common signs and symptoms of this syndrome are: 
ovulatory dysfunction, polycystic ovaries, hirsutism, obesity, raised ratio of 
luteinising hormone / follicle stimulating hormone, acne, androgenic alopecia 
and acanthosis nigricans.  
 
Although, the aetiology of PCOS remains unclear, four main hypotheses have 
been identified, which are not mutually exclusive and a summary of which, is 
shown in Table 2. 
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Table 2: Summary of the hypotheses involved in the aetiology of PCOS and their 
physiological effects 
Abbreviations: ACTH: Adrenocorticotropic Hormone, GnRH: Gonadotropin Releasing Hormone, 
LH: Luteinizing Hormone, P450c17α : a bifunctional cytochrome which has both 17a-hydroxylase 
and 17,20-lyase activities, SHBG: Sex Hormone Binding Hormone  
 
The “Insulin Hypothesis” proposes that a defect in insulin action could result in 
excess secretion of androgens, an excess that disrupts the ovulation process. 
The “Luteinising Hormone Hypothesis”  suggests that a primary defect in the 
hypothalamic-pituitary axis results in hyperandrogenism and anovulation. The 
“Ovarian Hypothesis” proposes that a defect in the ovarian synthesis and/or 
metabolism of sex steroids, leads to hyperandrogenism and anovulation. And 
finally, the “Cortisol Hypothesis”,proposes that a modification of the metabolic 
pathway of cortisol results in increased adrenal androgen production 
(Tsilchorozidou et al. 2003). 
Type of Hypothesis Proposed mechanism 
involved 
Physiological Effects References 
Cortisol Hypothesis  Modified cortisol 
metabolism, adrenal 
androgen production may 
rise up to 25% 
↑ levels of cortisol → ↑ 
secretion of ACTH  
Acceleration of activity of 
5α reductase:  
LIVER: cortisol → 5α -
dihydrocortisol 
SKIN: testosterone → 5α-
dihydrotestosterone 
URINE: 5α >5β cortisol 
metabolites  
 
Ehrmann et al.1992, 
1992, Moran and Azziz, 
2001, Rodin et al. 1994, 
Stewart et al. 1990, 
Turner et al. 1992 
Insulin Hypothesis  Positive correlation between 
fasting insulin and androgen 
levels, activity of the 
ovarian cytochrome 
P450c17α is decreased 
Increased production of 
progesterone to 
androstenedione and 
testosterone 
Reduction of hepatic 
synthesis of SHBG 
Burghen et al. 1980, 
Dunaif 1986, Franks et 
al. 1991, Holte et al. 
1995, Nestler and 
Jakubowicz 1996, Peiris 
et al. 1989, Robinson et 
al. 1992 
LH Hypothesis  
 
An increased sensitivity of 
the anterior pituitary gland  
to GnRH stimulation may 
lead to LH hypersecretion 
↑ LH may lead to increased 
ovarian androgen 
production as LH stimulates 
the ovarian theca cells 
together with insulin for 
steroid biosynthesis  
 
Balen et al. 1995, 
Dunaif 1986, Ehrmann 
et al 1995, Yen, Vela 
and Rankin 1970, 
Venturoli et al. 1988 
Ovarian Hypothesis  Increased ovarian androgen 
production due to 
upregulation of the 
enzymatic system of 
steroidogenesis 
↑production of 17α-
hydroxyprogesterone and 
androstenedione in 
response to ↑LH  
Ehrmann et al. 1992, 
Nelson et al. 1999, 
Nelson et al. 2001, 
Rosenfield et al. 1990 
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To conclude, PCOS includes a cluster of symptoms and signs, and its metabolic 
disturbances may increase the risk of specific diseases and health conditions 
such as cardiovascular disease, type 2 diabetes, hypertension, gestational 
diabetes, spontaneous abortion, breast and endometrial cancer and infertility 
(Herriot et al. 2008). However, despite the proposed mechanisms suggested to 
explain the origin of PCOS and the increasing consensus that its core features 
are insulin resistance, abnormal gonadotropin dynamics and  androgen excess, 
its exact aetiology still remains unknown. Thus, there is great need for further 
research to elucidate the causation of this syndrome. 
 
1.3 PCOS associated comorbidities 
 
PCOS has been associated not only with a variety of reproductive and skin 
disorders, but also with an adverse metabolic profile (Figure 1) which includes 
systemic dysfunctions such as insulin resistance with compensatory 
hyperinsulinemia, hypertension and dyslipidemia (DeUgarte et al. 2006, 
Escobar-Morreale et al. 2011). Interestingly, these dysfunctions mirror the ones 
observed in individuals with type 2 diabetes mellitus (T2DM) (Sattar, 2009). In 
the long term, PCOS patients may develop impaired glucose tolerance (IGT), 
which can eventually lead to T2DM with increased risk for cardiovascular and 
cerebrovascular diseases (Wild et al. 2000, Christian et al. 2003, De Groot et al. 
2011). Moreover, a number of prospective studies suggest that the prevalence 
of both IGT and T2DM, is higher in women with PCOS when compared with 
weight and age matched controls without PCOS (Ehrmann et al. 1999, Legro et 
al. 1999). It has also been documented, that the first degree relatives of PCOS 
patients may be at high risk for T2DM and IGT (Colilla et al. 2001, Legro et al. 
2002, Norman et al. 1996, Yildiz et al. 2003), although further large scale family 
studies are limited. 
15 
 
 
Figure 1: Biochemical and clinical abnormalities observed in PCOS, adapted from (Tsilchorozidou 
et al. 2004) LH: Luteinizing Hormone, SHBG: Sex Hormone Binding Globulin , IGF: Insulin Growth 
Factor,  IGFP: Insulin Growth Factor Peptide , DHEA(S): Dehydroepiandrosterone (Sulphate) 
 
 
At least half of the women with PCOS are obese (Must et al. 1999; Boeka et al. 
2008), which could imply that PCOS patients may have a predisposition towards 
obesity (Hoeger and Oberfield 2012). Interestingly, the incidence of obesity 
within the PCOS population is higher than the one in the general population 
(40.4% among women in the UK). However, since the phenotype of PCOS has 
been mainly based on findings in a self or otherwise referred population, and not 
on an unselected population, this percentage may be overestimated (Ezeh, Yildiz 
and Azziz 2013). Moreover, obese women with PCOS, may face additional 
barriers in achieving weight loss, as compared to healthy women without this 
condition. This could be either due to the observed decreased postprandial 
thermogenesis which is also statistically correlated with the degree of reduced 
insulin sensitivity (Robinson et al. 1992) or due to specific eating behaviours 
(e.g. emotional eating) and snacking patterns (cravings for sweet and savoury 
snacks which are high in calories and fat) that are observed among 
overweight/obese women with PCOS (Jeanes et al. 2010).  
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However, additional research is needed to compare the actual rate of weight loss 
between obese PCOS and non PCOS.  
 
1.4 Quality of Life in PCOS 
 
In addition to the metabolic and reproductive disorders, women with PCOS are 
at increased risk of emotional distress and poorer quality of life (QOL) 
(Elsenbruch et al. 2003, Himelein and Thatcher, 2006, Jones et al. 2008, 
McCook et al. 2005), a fact that may have either pathophysiological and/or 
psychosocial impact (Farrell and Antoni 2010). Chronic disease is a risk factor for 
depressive disorders and decreased QOL (Wilhelm et al. 2003), however many of 
the PCOS features, such as menstrual irregularities, difficulties in conceiving and 
problems with the physical appearance (e.g. acne, hirsutism, excess weight, 
body shape etc.), intensify the self - dissatisfaction and perceived lower QOL 
(Elsenbruch et al. 2003, Grogan 1999, McCook et al. 2005).  
 
Moreover, the prevalence of depressive symptoms and anxiety among PCOS 
patients is high (Hahn et al. 2005, Trent et al. 2002, Weiner et al. 2004), a fact 
that suggests that these patients may also present with low self esteem and 
unhealthy eating behaviours. Furthermore, depressive and anxiety episodes 
appear to be significantly increased when compared to either weight-matched 
(Weiner et al. 2004) or aged-matched (Elsenbruch et al. 2003) healthy women. 
In addition, Moran et al (2010), in an observational, cross-sectional study (24 
women with PCOS versus 22 women without PCOS), identified that women with 
PCOS perceive themselves as individuals with the increased risk of remaining 
overweight/obese, a belief that can influence further their relationship with food. 
 
Overall, the psycho-social dimensions of this syndrome negatively impact on the 
QOL of the affected women as well as their family and friends.  
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1.5 Treatment for PCOS  
 
The first-line treatment for PCOS includes diet and lifestyle interventions (Moran 
et al. 2009) to promote a healthy weight, especially in cases of overweight and 
obese patients. Certain medications are also used to manage the accompanied 
symptoms.  For example: 
 Metformin, is prescribed to regulate the ovulation rates in women with 
PCOS (Lord et al. 2003),  
 the Combined Oral Contraceptive Pill is given to alleviate acne and 
hirsutism (Glueck et al. 2002), however this may lead to weight gain due 
to possible fluid retention and increased appetite 
 Clomifene Citrate or Gonadotrophins or ovarian drilling (a specialised 
laparoscopic or surgical procedure) are applied specifically for ovulation 
induction (Saleh and Khali 2004).  
 
Up to date, the dietary treatment is focused on weight loss in overweight/obese 
women with PCOS. Interestingly, lean women with PCOS are also advised to 
follow a healthy nutrition, due to their increased risks for type 2 diabetes and 
other metabolic abnormalities (Herriot et al., 2008). In cases of excess weight, 
even a modest weight loss of 2-5% total body weight may restore ovulation 
(Clark et al. 1998, Crosignani et al. 2003, Huber-Buchholz et al. 1999, Moran et 
al. 2006, Tolino et al. 2005), improve the reproductive hormonal profile 
(Jakubowicz and Nestler 1997, Kiddy et al. 1992, Mavropoulos et al. 2005, 
Moran et al. 2006, Tolino et al. 2005), and achieve an improvement in insulin 
sensitivity (Holte et al. 1995, Huber-Buchholz et al. 1999, Jakubowicz and 
Nestler 1997, Kiddy et al. 1992, Mavropoulos et al. 2005). However, there is still 
a debate over what should be considered the optimal diet composition, resulting 
in the lack of accurate advice given by dietitians (Herriot et al. 2008). 
 
For example, Liepa et al (2008) proposed that patients with PCOS should 
consume a diet that follows the same nutritional guidelines as for patients with 
T2DM (Liepa et al. 2008). On the other hand, Kasim-Karakas et al (2008), after 
conducting a 2-month free-living randomised study at a PCOS clinic, suggested 
that a hypocaloric diet supplemented with an extra protein meal, results in 
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greater weight loss when compared to a hypocaloric diet supplemented with 
simple carbohydrates.  
 
Nicholson et al (2010), attempted to present the efficacy of long term (≥12 
months) non-surgical weight loss interventions and to identify behavioural 
strategies for obese women with PCOS in a systematic review. It was concluded 
that there is not enough evidence for suggesting the ideal weight loss approach 
in the area of PCOS. This was attributed to the heterogeneity of the 
interventions, poor description of the protocol in some cases and lack of 
comparable data. In more detail, different criteria were used for PCOS diagnosis 
across the studies, a variety of dietary interventions was applied (plus 
medications and/or behavioural change elements), the duration of the 
interventions was variable and in some cases there was a lack of a control 
group. The following table, summarises the included studies and weight loss 
achieved.  
 
 
 
 
 
 
 
 
 Table 3: Summary table of the studies included in the systematic literature review by Nicholson et al. 2010 
Principal author Intervention Group A results Group B results Group C results Group D results 
Hoeger et al. 2004 Group A: Metformin (n = 9) 
Group B:Lifestyle change + placebo (n = 11) 
Group C:Metformin + lifestyle change (n = 9) 
Group D:Placebo (n = 9) 
M: −6.5% weight LC + Pl: −6.8% weight LC + M: −8.9% weight Pl: −0.2% weight 
Lemay et al. 2006 Group A: rosiglitazone + diet for 6 mo (n = 15) 
Group B: oral contraceptive (EE/CPA) + diet for 6 mo (n = 13) 
At 6 mo, groups A and B commenced rosiglitazone and EE/CPA 
No significant weight change No significant weight 
change 
  
Gambineri et al. 2006 Group A: Diet + placebo (n = 20) 
Group B: Diet + metformin (n = 20) 
Group C: Diet + flutamide (n = 20) 
Group D: Diet + metformin + flutamide (n = 20) 
D + Pl: −5 ± 16 kg D + M: −4 ± 13 kg D + F: −9 ± 9 kg D + M + F: −10 ± 14 kg 
Glueck et al. 2006 Group A: Metformin + diet (n = 20) 
Group B: Diet (n = 3) 
M + D: −7.7% weight D: −3.3% weight   
Zulian et al. 2005 Group A (BMI < 25): spironolactone for 12 mo (n = 5) 
Group B (BMI > 25): spironolactone + diet for 12 mo (n = 7) 
No weight loss Mean BMI: −2 ± 4.7 kg/m2   
Glueck et al. 2003 Groups A and B: metformin for 12 mo 
Group A: pioglitazone for 10 mo (n = 13) 
Group B: metformin for 10 mo (n = 26) 
No weight loss Median: −6 kg weight   
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Principal author Intervention Group A results Group B results Group C results Group D results 
Glueck et al. 2006 Metformin + dietary advice (n = 89) Mean: (8.9% weight loss)    
Crosignani et al. 2003 Diet + physical exercise (n = 33) 76% (n = 25): ≥ −5% weight 
33% (n = 11): ≥ −10% weight 
   
Adapted from Nicholson et al. 2010. Abbreviations: M, metformin; LC, lifestyle change; Pl, placebo; D, diet; F, flutamide; BMI, body mass index. 
 Interestingly, Jeanes et al (2009) aimed to evaluate the advice given by 
dietitians to women with PCOS specifically in the UK. The patients were 
recruited via “Verity” (Verity is a charity that provides support to women 
across the UK, diagnosed with PCOS) , and the dietitians were contacted by 
the British Dietetic Association and its branches. Overall, 105 dietitians 
completed the survey, 206 patients filled in questionnaires (the 
questionnaires were tailored specifically for the study and included questions 
related to PCOS diagnosis, self reported symptoms, body weight, height and 
related nutritional advice obtained) and 196 completed a 7-day food diary. 
According to the data received, 57% of the PCOS patients were following 
either a low glycaemic index diet (34%), or a weight loss diet (16%) or a 
combination (26%).  
 
Moreover, 73% of overweight women with PCOS were not following a diet to 
initiate weight loss. Interestingly, only 15% of the participants had seen a 
registered dietitian, while all the others were following a diet based on 
commercial diet books either prescribed or via word of mouth. In addition, 
the majority of the patients who were following an exercise program 
mentioned a significant improvement in their symptoms. 
 
 Overall, although PCOS patients recognise the importance of diet, a scientific 
consensus on the ideal nutritional prescription is still lacking while at the 
same time is very much needed (Jeanes et al. 2009). 
 
 
 
1.5.1 Very low calorie diets (VLCDs) 
 
A very low calorie diet (VLCD), can be defined as a nutrition plan that 
provides ≤800kcal per day (National Task Force 1993) and it is comprised of 
either conventional meals or synthetic formulas –e.g. shakes, soups, bars – 
or a combination of both. However, modern VLCDs should not be confused 
with the VLCDs used in the 1970’s, the latter being associated with a number 
of deaths, mainly due to inadequate provision of minerals, vitamins and 
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protein (van Itallie, 1978, Centre For Disease Control, 1979). Modern 
commercial VLCDs take into consideration the maintenance of lean body 
mass by fortification of the formulae with high levels of good quality protein 
and with essential electrolytes (sodium, potassium, bicarbonate, chloride, 
calcium, phosphates), fatty acids, minerals and vitamins (Dhindsa et al. 
2003). This approach is safe and according to the National Institute for 
Health and Clinical Excellence (NICE, http://guidance.nice.org.uk/CG43/), it 
can be used up to 3 months, in medically supervised conditions for obese 
patients who fail to meet their weight loss target using a standard low fat, 
calorie deficient diet (CDD).  
 
A VLCD can lead to an average weekly weight loss of 1.5-2.5 kg, versus the 
0.4-0.5 kg loss achieved with the CDDs (Atkinson et al. 1993). Moreover, the 
average weight loss at 12 weeks for an obese individual is approximately 20 
kg on a VLCD, whereas it is only 8 kg on a CCD (Atkinson et al. 1993).  
Consequently, a VLCD could be a good alternative for obese PCOS patients -
both in the short and longer term-, who may face difficulties losing weight 
despite following standard approaches. 
 
However, the majority of the research around the area  of weight loss in 
PCOS has focused on several dietary approaches: high protein diet (30% 
protein), monounsaturated fatty acid (MUFA) enriched diet (17% MUFA), low 
fat (6% fat)-high carbohydrate (81% carbohydrates, CHO) diet, healthy 
eating (50% CHO, 20% protein, 30% fat), very low calorie diet (VLCD), high 
fat diet (25% CHO, 15% protein, 60% fat).  Only 3 papers have examined 
the effect of VLCDs on PCOS (Tolino et al. 2005, Van Dam et al. 2002, 2004). 
The research by Tolino et al. (2005) showed that weight loss  achieved after 
a 7 –month caloric restriction (4 weeks VLCD and the rest duration LCD) may 
lead to a decrease of the free testosterone and fasting insulin levels and 
induce further improvement in menstrual regularities. Van Dam et al (2002), 
carried out an interesting study to investigate the effect of short term dieting 
in LH homeostasis in obese patients with PCOS. According to the 
observations, both basal and pulsatile secretion of LH was three times higher 
in PCOS patients as compared to matched individual without PCOS, implying 
that caloric restriction failed to normalise the LH secretion.  On the contrary, 
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total testosterone, glucose and insulin levels were decreased. In another 
study, the same researchers (Van Dam et al. 2004), examined 15 obese 
participants with PCOS. Patients were studied at baseline (occasion 1), after 
a week of VLCD (occasion 2) and then after achieving 10% weight loss of 
their original weight via a VLCD (occasion 3).  Results suggested that after 
the weight loss achieved, the estradiol depentant negative feedback on LH 
was normalised and lead to resumption of ovulation.  
 
1.6 Summary  
 
PCOS is one of the most common female endocrine disorders, and it has been 
associated with a variety of reproductive and skin disorders, as well as with 
an adverse metabolic profile. In addition, it is associated with negative 
psycho-social symptoms and overall poorer quality of life for the women 
involved. 
 
However, there is still a lack of consensus over the diagnostic criteria and 
large scale, well planned trials investigating its prevalence among different 
populations are limited. Also, despite the fact that the first-line treatment 
option for PCOS is diet and lifestyle interventions, optimal dietary guidelines 
are missing. Although there is evidence supporting the efficacy and safety of 
VLCDs, this approach has not been adequately investigated in the area of 
PCOS and both short and longer term data are still needed.  
 
2. Aim 
 
The aim of this project was to investigate how overweight and obese women 
with PCOS respond to a commercial VLCD with a behavioural component as 
compared to women without PCOS.  
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2.1 Objectives 
 
1) To identify the baseline characteristics of women with PCOS 
undertaking a commercial VLCD in conjunction with a behavioural 
component  
2) To determine whether women with PCOS present differently to women 
without PCOS following the same approach  
3) To assess and compare the weight loss achieved at 12 weeks by 
women with PCOS versus women without PCOS 
4) To assess and compare the weight loss achieved at 12 months by 
women with PCOS versus women without PCOS 
 
3.Methodology 
 
3.1 Project design 
 
This project involved a retrospective analysis of a subset of the original 
LighterLife (LL) database which contained observations and measurements 
for every client that followed this commercial approach. The subset included 
anonymised data from women 18-75 years of age, with BMI≥28kg/m2, who 
followed the LL Total approach from January 2006 until December 2011. The 
parameters that were originally planned to be analysed are: Age (yrs), 
Weight (kg), Stature (m), BMI (kg/m2), Systolic Blood Pressure (mmHg), 
Diastolic Blood Pressure (mmHg), Smoking Status, Ethnicity (self reported), 
Attendance Rates, Foodpacks Consumed, Waist Circumference (cm), Hip 
Circumference (cm), Bust Circumference (cm), Medications.  
 
However, information was either not available or available in an unsuitable 
for analysis format, thus the final analysis included the parameters in the 
following figure (Figure 2). 
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Figure 2: Parameters used for the epidemiological analysis of the LL database 
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The project was divided into 3 main parts (Figure 3): 
 
i) The first part focused on the comparison of the baseline presentation of 
overweight/obese women with and without PCOS. Moreover, the prevalence 
of PCOS among the different ethnic groups was investigated.  
 
ii) The second part examined whether overweight/obese participants with 
PCOS patients lose different amounts of total weight and at a different rate as 
compared to obese non-PCOS after they had all followed the LL programme 
for 12 weeks. 
 
iii) The third part investigated whether the total weight loss differs between 
overweight/obese women with and without PCOS, at 12 months after the 
initiation of the VLCD. 
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Figure 3: Schematic presentation of the database analysis (EN implies that the specific task was done by the 
research student, LL implies that the specific task was done by the data analyst of LighterLife) 
 
*age (yrs), stature (m), body weight (kg), BMI (kg/m2), waist circumference (cm), hip circumference (cm), bust circumference (cm), 
waist to hip ratio (WHR), stature to waist ratio (SHR), systolic and diastolic blood pressure (mmHg) 
 
**body weight (kg), BMI (kg/m2), waist circumference (cm), hip circumference (cm), bust circumference, waist to hip ratio (WHR), 
stature to waist ratio (SHR), systolic and diastolic blood pressure (mmHg) and medications (Defined Daily Dose) 
LighterLife Database 
Data extraction 
First Part Second Part Third Part 
Identification of total PCOS 
patients (LL) 
Identification of obese 
women who enrolled to the 
12 week VLCD (LL) 
Identification of obese women that 
enrolled to the 12 week VLCD and 
for whom data are available for 12 
months since their first visit (LL) 
Identification of baseline 
differences in the 
presentation of PCOS versus 
non-PCOS (EN)* 
Matching obese women with 
and without PCOS for age 
and BMI (EN) 
Identification of baseline 
differences in the presentation 
of obese women with and 
without PCOS(EN)* 
Grouping of PCOS and non-
PCOS participants according 
to their ethnic origin (EN) 
Identification of baseline 
differences in the presentation 
of matched obese women with 
and without PCOS (EN) ** 
Comparison of the 2 groups for the 
amount of time spent on the 
weight loss phase before entering 
the management phase (EN) 
Comparison of ethnic 
groups for baseline 
differences (EN) * 
ITT and completers 
assessment of the weekly rate 
of weight loss over the 12 
week period and comparison 
between the two groups (EN) 
Observation and 
comparison of the total and 
monthly changes** 
between and within the 2 
groups (EN) 
Comparison of ethnic 
groups for baseline 
differences (EN) * 
Observation and 
comparison of the monthly 
changes** for each and 
between the 2 groups (EN) 
Comparison of the attendance 
rates within and between the 
groups + examination whether 
these are associated with the 
rate of weight loss (EN) 
Comparison of the 
attendance rates within and 
between the groups + 
examination whether these 
are associated with the rate 
of weight loss (EN) 
Assessment and 
comparison of the effect of 
weight loss ** within and 
between the 2 groups (EN) 
Comparison of the total 
amount of food packs 
purchased among groups 
as a surrogate to assess 
attendance (EN) 
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3.2 The LighterLife Total Approach  
 
The LighterLife Total is a nutritionally balanced VLCD combined with a 
behavioural programme and it is one of the several approaches used by 
LighterLife. Potential clients (both men and women) can follow LL Total if 
they either have BMI≥30 kg/m2 or BMI ≥28-29.9kg/m2 plus a waist 
circumference >88cm in women and >102 cm in men. 
 
Initially, for the prospective client to enrol, a self - declared medical history 
needs to be filled in, which is later assessed by the LighterLife (LL) weight 
management counsellor. Then, the individual completes the Client 
Information Form (CIF, appendix), which will be checked by the medical 
department of the company. If any of the exclusion criteria are applicable 
(see section of Study Participants), the potential client will not be allowed to 
enrol.  On the other hand, if the potential participant appears to be suitable, 
the Health Questionnaire (HQ, appendix) will be completed by their general 
practitioner or practice nurse, to confirm their self-declared information on 
the previously submitted forms. This questionnaire also includes details on 
past medical history, current blood pressure values and medications. After 
this step, and if all the inclusion criteria are met, the participant can start the 
LighterLife Total Programme. Then, throughout the active weight loss phase, 
an ongoing check up (OCU, appendix) is performed every 28 days, by a 
general practitioner or a practice nurse, where blood pressure is checked and 
medications may be adjusted. Below is a summary on patient’s data 
acquisition (Table 4). 
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Table 4: Data Acquisition for LL clients 
 
According to the protocol of the LL Total, participants replaced conventional 
food with Foodpacks (soups, shakes, bars). These provide a daily average 
intake of 550kcal, 50g protein, 50g carbohydrate, mean 17g fat, 10-17gr 
fibre and at least 100% of RDAs for vitamins and minerals. Participants were 
advised to stay adequately hydrated while on the programme.  
 
The LL Total Programme has two distinctive stages: active weight loss and 
weight management. Time spent on the weight loss period depends on the 
starting weight. However, in accordance with the National Institute for Health 
and Clinical Excellence (NICE, http://guidance.nice.org.uk/CG43/), 
participants were following the VLCD approach for up to 3 months. In case 
that further time was required, then the clients resumed the VLCD, after 
following a 7-day low calorie diet. 
 
During each stage, the clients attend weekly group meetings of 4-12 people 
delivered by a trained LL counsellor, utilising group support and counselling 
to encourage long term behavioural modification and weight management. 
The behaviour change techniques applied, borrow elements from the 
Data Method of Acquisition 
Information regarding ethnicity, smoking status and 
age (yrs) 
Health Questionnaire submitted to the central 
LL database by the LL counsellors 
Data on body weight (kg), stature (m), BMI (kg/m2), 
waist circumference (cm), bust circumference (cm), 
hip circumference (cm) and smoking status  
Submitted to the central LL database by the 
LL counsellors 
Information on medications, blood pressure (mmHg) 
and disease status (PCOS).  
Extracted from the medical form and then 
submitted to LL database 
Updated every 28 days on any changes regarding 
medications, blood pressure and health status 
Submitted through the ongoing check up form 
to the central LL database by the LL 
counsellors 
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principles of Cognitive Behavioural Therapy (CBT) and Transactional Analysis 
(TA) -which form the transactional cognitive behavioural therapy (TCBT®)- 
and from the addiction/change theory (Buckroyd and Rother 2007, Chaston 
and Dixon 2008, Cooper et al. 2003). Following the active weight loss period, 
participants are gradually reintroduced to conventional food, following a 
standardised protocol (management), where foodpacks are gradually 
decreased while the consumption of the conventional food is increased 
(Appendix).  
 
3.3 Study Participants  
 
Women aged between 18-75 years, with BMI≥28kg/m2, who followed the 
LighterLife Total approach from January 2006 until December 2011, were 
included in the analysis.  Moreover, due to the LighterLife protocol, the 
following exclusion criteria were applicable:  
 
 type 1 diabetes  
 porphyria  
 total lactose intolerance  
 major cardiovascular or cerebrovascular disease  
 history of renal disorder or hepatic disease  
 active cancer  
 currently suffering from thrombosis or have taken medication for this 
condition within the last six months 
 serious illness, injury, trauma and/or surgery in the last 3 months  
 epilepsy, seizures, convulsions, major depressive disorder, psychotic 
episodes, schizophrenia, bipolar disorders, delusional disorders  
 current suffering from anorexia, bulimia or undergoing treatment for 
any other eating disorder  
 due to undergo serious treatment /surgery  
 are pregnant or breastfeeding  
 have given birth or had a miscarriage in the last 3 months  
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3.4 Acquisition of Data from LighterLife 
 
 
The research student composed a script for data extraction according to the 
study objectives. The script was later translated into standard system commands 
(Structured Query Language (SQL)) and then appropriate software (Microsoft 
Access) was used to generate data. When the new database was generated, the 
data analyst at LighterLife performed a process known as database cleansing. 
This involved visual inspection to investigate eligibility, validity and integrity of 
the records. For example it was checked whether all the data were consistently 
formatted, if there were any duplicates, missing values, if there was an increase 
or decrease in the weekly body weight >10kg etc. Due to the confidential nature 
of database cleansing –the data analyst occasionally needed to check the 
original participant files or to contact the LL counsellor of a participant-, the 
research student was not allowed  to perform this procedure. 
 
After the database cleansing, a subset of the original LL database (women 18-75 
years of age, with BMI≥28kg/m2, who followed the LL Total approach from 
January 2006 until December 2011) was sent to the research student and then 
the subset was checked by the student for any outliers before proceeding to 
further statistical analysis. This involved sorting cases using Microsoft Excel and 
searching for any extreme values that were outwith an expected range. In cases 
of extreme values, the LL data analyst was consulted before their removal.  
 
The initial number of PCOS participants that were identified in the database was 
574, but after data cleansing and checking for outliers 59 clients with PCOS were 
removed (515 remained). Regarding the non-PCOS clients, the original number 
was 109,412 but 7,317 were removed, leaving 102,095 participants for further 
analysis.  
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3.5 Statistical Analysis 
 
Analysis of the individual parameters was performed by the use of descriptive 
statistics (e.g. mean, standard deviation). Then, all variables were assessed for 
normality using the Kolmogorov-Smirnov test. As the parameters were either 
normal or very close to being normally distributed, a set of appropriate 
parametric tests were executed. Specifically, differences of continuous variables 
between groups were assessed using an unpaired two-tailed t-test and 
differences within groups, were assessed via a paired t-test. If more than 2 
groups were compared, analysis of variance (ANOVA) and other post hoc tests 
were used (Bonferroni). For categorical outcomes, non-parametric tests were 
used. All P-values were 2-sided, and a P-value of < 0.05 was considered as 
statistically significant. Analyses were performed with SPSS (SPSS Inc., Chicago, 
Illinois). 
 
To avoid any potential biases stemming from the comparison of the large 
population in the non PCOS group (n=102,095) versus the much smaller sample 
of PCOS women (n=515), all the analyses were repeated for a randomly 
selected sample of 515 non PCOS women through a specific function on using 
SPSS. This process involves drawing a random sample from the whole 
population via the random selection procedure that is available on SPSS. 
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4.Results 
 
4.1 Baseline Characteristics of LighterLife clients with PCOS versus 
without PCOS 
 
There were 515 participants with PCOS and 102,095 who did not have PCOS 
(non-PCOS), out of a total sample of 102,610. The detailed baseline 
characteristics of the above groups are shown in Table 5. 
 
Table 5: Comparison of baseline characteristics between PCOS (n=515) and non PCOS 
(n=102,095) participants 
 
Parameter All (n=102,610) 
Non PCOS 
(n=102,095) 
PCOS (n=515) P† 
Age (yrs) 41.8±11.3 41.9±11.3 34.5±8.2 <0.001* 
Height (m) 1.64±0.07 1.64±0.07 1.65±0.07 0.018* 
Weight (kg) 97.9±16.9 97.8±17.0 105.7±19.3 <0.001* 
BMI (kg/m2) 36.4±5.8 36.4±5.8 39.01±6.6 <0.001* 
Bust (cm) 
117.2±10.9 
(n=25,248) 
117.2±10.9 
(n=25,137) 
122.5±12.1 
(n=111) 
<0.001* 
Hip (cm) 
125.1±12.3 
(n=25,119) 
125.05±12.3 
(n=25,009) 
130.5±12.1 
(n=110) 
<0.001* 
Waist (cm) 
109.9±12.9 
(n=25,247) 
109.9±12.9 
(n=25,136) 
115.9±15.0 
(n=111) 
<0.001* 
WHR 
0.88±0.07 
(n=25,101) 
0.88±0.07 
(n=24,991) 
0.89±0.09 
(n=110) 
0.335 
Pulse/min 
75.8±9.3 
(n=101,951) 
75.8±9.3 
(n=101,440) 
76.6±8.8 
(n=511) 
0.067 
Systolic BP 
(mmHg) 
128.9±15.1 
(n=101,951) 
129.0±15.13 
(n=101,440) 
127.5±12.6 
(n=511) 
0.007* 
Diastolic BP 
(mmHg) 
81.1±10.6 
(n=101,951) 
81.1±10.6 
(n=101,440) 
81.4±10.2 
(n=511) 
0.536 
Total 
Medications 
1.0±1.6 1.0±1.6  2.5±1.6  <0.001* 
Values are means ± standard deviation. Abbreviations: BMI, Body Mass Index; WHR, Waist to Hip Ratio. 
†Significance level of the difference between PCOS and non PCOS groups at baseline, calculated using an 
independent t-test 
* marks the significant difference between the 2 groups at baseline, p < 0.05, calculated using an independent 
t-test 
 
 
To avoid any potential biases stemming from the comparison of the large 
population in the non PCOS group (n=102,095) versus the much smaller sample 
34 
 
of PCOS women (n=515), the analysis was repeated for a randomly selected 
sample of 515 non PCOS women through SPSS. According to GPower 3.1, the 
choice of 515 participants in each group, would allow us to identify both small 
and medium effect size differences on weight, with the statistical power of 89% 
and 100% accordingly.  
 
This analysis gave similar results except for height, where there was no longer a 
statistical difference between the groups (1.65±0.07 versus 1.64±0.07, 
p=0.054). 
 
Table 6 : Comparison of baseline characteristics between PCOS (n=515) and randomly 
selected non PCOS (n=515) 
 
Parameter All (n=1,030) Non PCOS 
(n=515) 
PCOS (n=515) P† 
Age (yrs) 38.4±10.7 
42.40±11.5 
34.5±8.2 <0.001* 
Height (m) 1.64±0.07 
1.64±0.07 1.65±0.07 0.054 
Weight (kg) 101.5±18.6 
97.4±16.9 105.7±19.3 <0.001* 
BMI (kg/m2) 37.7±6.4 
36.3±5.8 39.01±6.6 <0.001* 
Bust (cm) 119.5±11.5 
(n=233) 
116.7±10.1 
(n=122) 
122.5±12.1 
(n=111) 
<0.001* 
Hip (cm) 127.8±12.2 
(n=232) 
125.4±11.9 
(n=122) 
130.5±12.1 
(n=110) 
0.001* 
Waist (cm) 113.2± 14.4 
(n=233) 
110.8±13.4 
(n=122) 
115.9±15.0 
(n=111) 
0.007* 
WHR 
0.89±0.07 
(n=232) 
0.88±0.07 
(n=122) 
0.89±0.09 
(n=110) 
0.684 
Pulse/min 
76.2±9.02 
(n=1,022) 
75.8±9.3 
(n=511) 
76.6±8.8 
(n=511) 
0.148 
Systolic BP 
(mmHg) 
128.7±13.4 
(n=1,022) 
129.8±14.2 
(n=511) 
127.5±12.6 
(n=511) 
0.006* 
Diastolic BP 
(mmHg) 
81.6±10.5 
(n=1,022) 
81.8±10.8 
(n=511) 
81.4±10.2 
(n=511) 
0.556 
TotalMeds 
1.7±1.7 0.9±1.3 
2.5±1.6 
<0.001* 
Values are means ± standard deviation. Abbreviations: BMI, Body Mass Index; WHR, Waist to Hip Ratio. 
†Significance level of the difference between PCOS and non PCOS groups at baseline, calculated using an 
independent t-test 
* marks the significant difference between the 2 groups at baseline, p < 0.05, calculated using an independent 
t-test 
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4.1.1 BMI Categories 
 
 
In Table 7, the different BMI groups encountered in both the PCOS and the non-
PCOS group are presented. Then, the differences between PCOS and non PCOS 
for each BMI group were assessed. Proportions were compared using Chi-
square. 
 
Table 7: The different BMI groups encountered in the PCOS and non PCOS category  
 
BMI values 
BMI 
groups 
Non PCOS (%) PCOS (%) 
28-29 kg/m2 0 7,913 (7.8%) 22 (4.3%) 
30-34.9 kg/m2 1 41,388 (40.5%) 127 (24.7%) 
35-39.9 kg/m2 2 29,514 (28.9%) 159 (30.9%) 
40-44.9 kg/m2 3 14,489 (14.2%) 116 (22.5%) 
45-49.9 kg/m2 4 5,769 (5.7%) 55 (10.7%) 
>50.0 kg/m2 5 3,022 (3.0%) 36 (7.0%) 
 
 
The following table shows comparisons between the PCOS and non PCOS groups, 
using combined BMI groups this time (overweight, obesity class I and II, obesity 
class III). 
 
 
Table 8: Combined BMI groups encountered in the PCOS and non PCOS category 
 
BMI values  BMI groups Non PCOS (%) PCOS (%) 
28-29 kg/m2 1 7913 (7.8%) 22 (4.3%) 
30-39.9 kg/m2 2 70,902 (69.4%) 286 (55.5%) 
≥40.0 kg/m2 3 23,280 (22.8%) 207 (40.0%) 
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4.1.2 Blood Pressure 
 
 
Values for blood pressure (mmHg) and pulse (beats per minute, bpm) were also 
compared between the PCOS and non PCOS categories and within the different 
BMI groups (both unmerged and merged -overweight, obesity class I and II, 
obesity class III- ). This was done to identify possible differences within the 
different groups, because of the established association between high BMI and 
high blood pressure.  
 
Table 9: Comparison of Systolic and Diastolic Blood Pressure and Pulse, between PCOS 
and non PCOS participants at BMI group=0, (BMI= 28-29kg/m2) 
 
Parameter PCOS category N Mean±SD P† 
Systolic BP 
(mmHg) 
non PCOS 7,837 124.1±14.2 0.427 
PCOS 22 126.5±17.8  
Diastolic BP 
(mmHg) 
non PCOS 7,837 78.0±10.3 1.0 
PCOS 22 78.0±11.3  
Pulse  
(bpm) 
non PCOS 7,837 74.3±8.9 0.712 
PCOS 22 75.0±8.1  
 
Values are means ± standard deviation. 
†Significance level of the difference between PCOS and non PCOS groups at baseline, calculated using an 
independent t-test 
* marks the significant difference between the 2 groups at baseline, p < 0.05, calculated using an independent 
t-test 
 
 
Table 10: Comparison of Systolic and Diastolic Blood Pressure and Pulse between PCOS 
and non PCOS participants at BMI group=1 (BMI= 30-34.9kg/m2) 
 
 
Parameter PCOS category N Mean±SD P† 
Systolic BP  
(mmHg) 
non PCOS 41,121 126.7±14.5 0.09 
PCOS 126 124.9±11.9  
Diastolic BP 
(mmHg) 
non PCOS 41,121 79.7±10.2 0.49 
PCOS 126 79.1±11.0  
Pulse  
(bpm) 
non PCOS 41,121 75.1±9.1 0.90 
PCOS 126 75.2±8.5  
 
Values are means ± standard deviation.  
†Significance level of the difference between PCOS and non PCOS groups at baseline, calculated using an 
independent t-test 
* marks the significant difference between the 2 groups at baseline, p < 0.05, calculated using an independent 
t-test 
 
 
 
37 
 
Table 11: Comparison of Systolic and Diastolic Blood Pressure and Pulse between 
PCOS and non PCOS participants at BMI group=2 (BMI= 35-39.9 kg/m2) 
 
Parameter PCOS category N Mean±SD P† 
Systolic BP 
(mmHg) 
non PCOS 29,341 129.9±15.0 0.07 
PCOS 159 128.3±11.3  
Diastolic BP 
(mmHg) 
non PCOS 29,341 81.8±10.5 0.04* 
PCOS 159 83.5±10.2  
Pulse  
(bpm) 
non PCOS 29,341 76.1±9.3 0.241 
PCOS 159 77.0±8.9  
 
Values are means ± standard deviation.  
†Significance level of the difference between PCOS and non PCOS groups at baseline, calculated using an 
independent t-test 
* marks the significant difference between the 2 groups at baseline, p < 0.05, calculated using an independent 
t-test 
 
Table 12: Comparison of Systolic and Diastolic Blood Pressure and Pulse between 
PCOS and non PCOS participants at BMI group=3 (BMI= 40-44.9 kg/m2) 
 
Parameter PCOS category N Mean±SD P† 
Systolic BP 
(mmHg) 
non PCOS 14,411 132.3±15.2 0.001* 
PCOS 115 127.5±12.6  
Diastolic BP 
(mmHg) 
non PCOS 14,411 83.3±10.5 0.017* 
PCOS 115 80.9±8.6  
Pulse 
 (bpm) 
non PCOS 14,411 76.9±9.4 0.725 
PCOS 115 76.6±8.7  
 
Values are means ± standard deviation.. 
†Significance level of the difference between PCOS and non PCOS groups at baseline, calculated using an 
independent t-test 
* marks the significant difference between the 2 groups at baseline, p < 0.05, calculated using an independent 
t-test 
 
Table 13: Comparison of Systolic and Diastolic Blood Pressure and Pulse between 
PCOS and non PCOS participants at BMI group=4 (BMI= 45-49.9 kg/m2) 
 
Parameter PCOS category N Mean±SD P† 
Systolic BP 
(mmHg) 
non PCOS 5,726 134.9±12.0 <0.001* 
PCOS 54 127.2±13.1  
Diastolic BP 
(mmHg) 
non PCOS 5,726 84.5±8.6 0.004* 
PCOS 54 80.3±9.7  
Pulse  
(bpm) 
non PCOS 5,726 77.7±9.3 0.88 
PCOS 54 77.9±7.8  
 
Values are means ± standard deviation.  
†Significance level of the difference between PCOS and non PCOS groups at baseline, calculated using an 
independent t-test 
* marks the significant difference between the 2 groups at baseline, p < 0.05, calculated using an independent 
t-test 
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Table 14: Comparison of Systolic and Diastolic Blood Pressure and Pulse PCOS and 
non PCOS participants at BMI group=5 (BMI>50.0/m2) 
 
 
Parameter PCOS category N Mean±SD P† 
Systolic 
BP(mmHg) 
non PCOS 3,004 137.0±15.8 0.32 
PCOS 35 134.3±16.2  
Diastolic 
BP(mmHg) 
non PCOS 3,004 85.3±11.1 0.77 
PCOS 35 85.9±11.8  
Pulse (bpm) non PCOS 3,004 77.9±9.5 0.65 
PCOS 35 78.60±10.6  
Values are means ± standard deviation.  
†Significance level of the difference between PCOS and non PCOS groups at baseline, calculated using an 
independent t-test 
* marks the significant difference between the 2 groups at baseline, p < 0.05, calculated using an independent 
t-test 
 
 
Table 15: Comparison of Systolic and Diastolic Blood Pressure and Pulse 
between PCOS and non PCOS at Combined BMI Group 1 (BMI:28-29 kg/m2)   
 
Parameter PCOS category N Mean±SD P† 
Systolic 
BP(mmHg) 
non PCOS 7,837 124.1±14.2 0.427 
PCOS 22 126.5±17.8  
Diastolic 
BP(mmHg) 
non PCOS 7,837 78.0±10.3 1 
PCOS 22 78.0±11.3  
Pulse (bpm) non PCOS 7,837 74.3±8.9 0.712 
PCOS 22 75.0±8.1  
 
Values are means ± standard deviation.  
†Significance level of the difference between PCOS and non PCOS groups at baseline, calculated using an 
independent t-test 
* marks the significant difference between the 2 groups at baseline, p < 0.05, calculated using an independent 
t-test 
 
 
Table 16: Comparison of Systolic and Diastolic Blood Pressure between PCOS 
and non PCOS at Combined BMI Group 2 (BMI: 30-39.9 kg/m2)   
 
Parameter PCOS category N Mean±SD P† 
Systolic 
BP(mmHg) 
non PCOS 70,462 128.1±14.8 0.065 
PCOS 285 126.8±11.7  
Diastolic 
BP(mmHg) 
non PCOS 70,462 80.6±10.4 0.114 
PCOS 285 81.6±10.7  
Pulse (bpm) non PCOS 70,462 75.5±9.2 0.220 
PCOS 285 76.2±8.8  
Values are means ± standard deviation.  
†Significance level of the difference between PCOS and non PCOS groups at baseline, calculated using an 
independent t-test 
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* marks the significant difference between the 2 groups at baseline, p < 0.05, calculated using an independent 
t-test 
Table 17: Comparison of Systolic and Diastolic Blood Pressure between PCOS 
and non PCOS at Combined BMI Group 3 (BMI: ≥40.0 kg/m2)   
 
Parameter PCOS category N Mean±SD P† 
Systolic 
BP(mmHg) 
non PCOS 23,141 133.5±15.4 <0.001* 
PCOS 204 128.6±13.0  
Diastolic 
BP(mmHg) 
non PCOS 23,141 83.8±10.7 0.01 
PCOS 204 81.6±9.3  
Pulse (bpm) non PCOS 23,141 77.2±9.4 0.926 
PCOS 204 77.3±8.8  
Values are means ± standard deviation.  
†Significance level of the difference between PCOS and non PCOS groups at baseline, calculated using an 
independent t-test 
* marks the significant difference between the 2 groups at baseline, p < 0.05, calculated using an independent 
t-test 
 
 
4.1.3 Ethnic Categories within the PCOS and non PCOS sample 
 
 
The prevalence of different ethnic categories among the PCOS and non PCOS 
particpants. are shown at Table 18.  
 
Table 18: Prevalence of the different ethnicities in the PCOS and non PCOS group 
 
Due to low numbers encountered in the PCOS group, the different ethnic groups 
were combined: Asian (Indian, Pakistani, and Bangladeshi) and African (Black 
African, Black Caribbean and Black Other). The Chinese subgroup was not 
included, as it appeared only in the PCOS sample.  
 
 
 Ethnicity  
PCOS 
Category 
Caucasian Indian Bangladeshi Pakistani 
Black 
African 
Black 
Caribbean 
Black 
other 
Chinese 
Non PCOS 9,411 2,308 1,733 1,127 1,733 1,561 677 69 
PCOS 437 34  9 19 9 7 51 0 
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Table 19: Prevalence of combined ethnicities in the PCOS and non PCOS group  
 Ethnicity 
PCOS Category Asian African Caucasian 
PCOS 11.1% 4.1% 84.9% 
Non PCOS 3.8% 3.9% 92.3% 
 
As it can be seen from the above table, the prevalence of Asians in the PCOS 
category is almost 3 times more, than in the non-PCOS category. Also, an 
attempt to note any differences in the expression of the PCOS phenotype among 
the different combined ethnic groups was carried out by ANOVA.  
 
The same analysis was repeated for the random sample that was selected 
through SPSS.  
 
Table 20 : The different ethnic categories observed between PCOS (n=515) and randomly 
selected non PCOS (n=515) 
 
Ethnic Group Non PCOS PCOS Total 
Caucasian  484 437 921 
Indian  8 34 42 
Pakistani 10 19 29 
Black African 5 9 14 
Black Caribbean 3 7 10 
Bangladeshi 2 4 6 
Black Other 3 5 8 
Chinese 0 0 0 
Total  515 515 1,030 
 
As it can be seen from the table below, the prevalence of Asians in the PCOS 
category is again approximately 3 times more, than in the non-PCOS category. 
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Table 21: The combined ethnic categories observed between PCOS (n=515) and 
randomly selected non PCOS (n=515) 
Ethnic Group Non PCOS (%) PCOS (%) Total (%) 
Caucasian  484 (94.0%) 437(84.9%) 921 (89.4%) 
Asian 20 (3.8%) 57(11.1%) 77 (7.8%) 
Africans 11 (2.1%) 21(4.1%) 32 (3.1%) 
Total  515 (100%) 515 (100%) 1,030 
 
Table 22: Baseline characteristics among the different ethnic categories of the 
PCOS participants 
 
Parameter Ethnicity N Mean±SD 
Age (yrs) 
Asian 57 31.2±7.1 
African 21 35.6±8.2 
Caucasian 437 34.9±8.2 
Total 515 34.5±8.2 
Height (m) 
Asian 57 1.62±0.06 
African 21 1.65±0.08 
Caucasian 437 1.65±0.07 
Total 515 1.65±0.07 
Weight (kg) 
Asian 57 97.6±16.6 
African 21 114.3±24.0 
Caucasian 437 106.3±19.1 
Total 515 105.7±19.3 
BMI (kg/m2) 
Asian 57 37.2±5.9 
African 21 41.9±7.0 
Caucasian 437 39.1±6.7 
Total 515 39.0±6.6 
Waist (cm) 
Asian 13 111.3±14.3 
African 7 121.9±15.9 
Caucasian 91 116.1±15.0 
Total 111 115.9±15.0 
Hip (cm) 
Asian 13 124.2±9.6 
African 7 132.9±13.04 
Caucasian 90 131.2±12.2 
Total 110 130.5±12.1 
WHR 
Asian 13 0.89±0.07 
African 7 0.91±0.04 
Caucasian 90 0.89±0.09 
Total 110 0.89±0.08 
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WSR 
Asian 13 0.68±0.09 
African 7 0.73±0.08 
Caucasian 91 0.71±0.10 
Total 111 0.70±0.09 
Bust (cm) 
Asian 13 115.9±11.2 
African 7 131.4±16.7 
Caucasian 91 122.7±11.5 
Total 111 122.5±12.1 
Systolic BP 
(mmHg) 
Asian 57 123.3±13.1 
African 20 129.4±11.9 
Caucasian 434 128.0±12.4 
Total 511 127.5±12.6 
Diastolic BP 
(mmHg) 
Asian 57 80.2±10.4 
African 20 82.5±10.8 
Caucasian 434 81.5±10.2 
Total 511 81.4±10.2 
Pulse (bpm) 
Asian 57 78.2±9.3 
African 20 76.2±8.9 
Caucasian 434 76.4±8.7 
Total 511 76.6±8.8 
 
The above table shows the descriptive characteristics of the combined ethnic 
groups of PCOS participants, as determined by one-way ANOVA. Bonferroni 
post-hoc tests revealed that:  
 
 Asian women with PCOS were younger (yrs) than Caucasian women with 
PCOS (34.9±8.2 versus 31.2±7.1, p=0.004),  
 Asian women with PCOS were presented with less weight(kg) than the 
African (97.6±16.6 versus 114.3±24.0, p=0.002) and the Caucasian 
(97.6±16.6 versus 106.3±19.1 p=0.004),  
 Asian women with PCOS had lower BMI (kg/m2)than the African 
(37.2±5.9 versus 41.9±7.0, p=0.016),  
 Asian women with PCOS had smaller bust (cm) than African women 
(115.9±11.2 versus 131.4±16.7, p=0.018), 
  Asian women had decreased values of systolic blood pressure (mmHg) 
when compared to Caucasian (115.9±11.2 versus 122.7±11.5, p=0.023)  
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The same analysis was performed for the combined ethnic groups of the non 
PCOS participants (Table 23).  
 
Table 23: Baseline characteristics among the different ethnic categories of the 
non-PCOS participants 
Parameter Ethnicity N Mean±SD 
Age (yrs) 
Asian 3,855 36.6±10.4 
African 3,971 38.4±9.6 
Caucasian 94,200 42.2±11.3 
Total 102,026 41.9±11.3 
Height (m) 
Asian 3,855 1.61±0.06 
African 3,971 1.64±0.07 
Caucasian 94,200 1.64±0.06 
Total 102,026 1.6±0.07 
Weight (kg) 
Asian 3,855 91.1±15.0 
African 3,971 100±18.1 
Caucasian 94,200 98±16.9 
Total 102,026 97.8±17.0 
BMI (kg/m2) 
Asian 3,855 35.2±5.1 
African 3,971 37.0±6.2 
Caucasian 94,200 36.4±5.8 
Total 102,026 36.4±5.8 
Waist (cm) 
Asian 708 106.9±12.1 
African 890 110.0±12.9 
Caucasian 23,521 110.0±12.9 
Total 25,119 109.9±12.9 
Hip (cm) 
Asian 706 121.5±10.2 
African 885 124.9±12.0 
Caucasian 23,402 125.2±12.3 
Total 24,993 125.1±12.3 
WHR 
Asian 706 0.88±0.07 
African 885 0.88±0.08 
Caucasian 23,384 0.88±0.07 
Total 24,975 0.88±0.07 
WSR 
Asian 708 0.67±0.08 
African 890 0.67±0.08 
Caucasian 23,521 0.67±0.08 
Total 25,119 0.67±0.08 
Bust (cm) Asian 709 112.1±10.01 
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African 890 116.3±11.8 
Caucasian 23,521 117.4±10.9 
Total 25,120 117.2±11.0 
Systolic BP 
(mmHg) 
Asian 3,842 124.4±14.5 
African 3,935 126.7±15.1 
Caucasian 93,595 129.3±15.1 
Total 101,372 129.0±15.1 
Diastolic BP 
(mmHg) 
Asian 3,842 79.5±10.3 
African 3,935 80.8±11.3 
Caucasian 93,595 81.2±10.5 
Total 101,372 81.1±10.6 
Pulse (bpm) 
Asian 3,842 76.9±9.3 
African 3,935 76.7±9.6 
Caucasian 93,595 75.8±9.3 
Total 101,372 75.8±9.3 
 
The Bonferroni post-hoc tests showed that the differences between the ethnic 
categories were more eminent in the non PCOS group.  
 
Age 
 Asian women were younger (yrs) than African and Caucasian (36.6±10.4 
versus 38.4±9.6, p<0.001 and 36.6±10.4  versus 42.2±11.3, p<0.001) 
 African women were younger (yrs) than Caucasian (38.4±9.6 versus 
42.2±11.3, p=0.009  
 
Weight and BMI 
 Asian women were presented with less weight (kg) than Caucasian 
(91.1±15.0 versus 98±16.9, p<0.001) 
 African were presented with more weight (kg) than Caucasian and Asian 
(100±18.1 versus 98±16.9, p<0.001 and 100±18.1 versus 91.1±15.0, 
p<0.001) 
 
Waist, Hip and Bust circumferences 
 Both African and Caucasian had wider waistline (cm) (110.0±12.9 versus 
106.9±12.1, p<0.001 and 110.0±12.1 versus 106.9±12.1, p<0.001) and 
hip circumference (cm) than the Asians (124.9±12.0 versus 121.5±10.2, 
p<0.001 and 125.2±12.3 versus 121.5±10.2, p<0.001) 
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 Asian had smaller bust size (cm) than both Africans and Caucasians 
(112.1±10.01 versus 116.3±11.8, p<0.001 and 112.1±10.01 versus 
117.4±10.9, p<0.001) 
 
Systolic and Diastolic BP 
 Caucasian had higher systolic pressure (mmHg) than Asians and Africans 
(129.3±15.1 versus 124.4±14.5 ,p<0.001 and 129.3±15.1 versus 
126.7±15.1, p<0.001 ) 
 
 Asian had lower systolic blood pressure (mmHg) than African (124.4±14.5 
versus 126.7±15.1, p<0.001) 
 
Pulse 
Asians and Africans had higher pulse (bpm) than Caucasians (76.9±9.3 versus 
75.8±9.3, p<0.001 and 76.7±9.6 versus 75.8±9.3, p<0.001). 
 
At the following tables, an ANOVA was performed to analyse for the differences 
between PCOS and non PCOS, within the same ethnic group.  
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Table 24: Baseline characteristics in the Asian Subgroup between the PCOS and 
non PCOS participants 
 
 PCOS 
Category 
N Mean± SD P† 
Age (yrs) 
non PCOS 3,855 36.61±10.4 <0.001
* 
PCOS 57 31.16±7.1  
Total 3,912 36.53±10.3  
Height (m) 
non PCOS 3,855 1.61±0.06 0.108 
PCOS 57 1.62±0.06  
Total 3,912 1.61±0.06  
Weight (kg) 
non PCOS 3,855 91.1±15.0 0.001* 
PCOS 57 97.6±16.6  
Total 3,912 91.2±15.1  
BMI (kg/m2) 
non PCOS 3,855 35.2±5.1 0.005* 
PCOS 57 37.2±5.9  
Total 3,912 35.23±5.2  
Systolic BP 
(mmHg) 
non PCOS 3842 124.4±14.5 0.545 
PCOS 57 123.3±13.1  
Total 3,899 124.4±14.5  
Diastolic BP 
(mmHg) 
non PCOS 3,842 79.5±10.3 0.632 
PCOS 57 80.2±10.4  
Total 3,899 79.5±10.3  
Pulse 
(bpm) 
non PCOS 3842 76.9±9.3 0.270 
PCOS 57 78.3±9.3  
Total 3899 76.9±9.3  
Values are means ± standard deviation. Abbreviations: BMI, Body Mass Index 
†Significance level of the difference between PCOS and non PCOS groups at each time point, 
calculated using an independent t-test 
* marks the significant difference between the 2 groups, p < 0.05 
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Table 25: Baseline characteristics in the African Subgroup between the PCOS 
and non PCOS participants 
 PCOS 
Category 
N Mean± SD P† 
Age (yrs) 
non PCOS 3,971 38.4±9.6 0.190 
PCOS 21 35.6±8.2  
Total 3,992 38.4±9.6  
Height (m) 
non PCOS 3,971 1.64±0.07 0.676 
PCOS 21 1.65±0.08  
Total 3,992 1.64±0.07  
Weight (kg) 
non PCOS 3,971 100.0±18.1 <0.001
* 
PCOS 21 114.3±  
Total 3,992 100.1±18.2  
BMI (kg/m2) 
non PCOS 3,971 37.040±6.2 <0.001
* 
PCOS 21 41.878±7.0  
Total 3,992 37.065±6.2  
Systolic BP 
(mmHg) 
non PCOS 3,935 126.7329±1
5.1 
 
PCOS 20 129.4±11.9 0.431 
Total 3,955 126.7±15.0  
Diastolic BP 
(mmHg) 
non PCOS 3,935 80.8±11.3 0.509 
PCOS 20 82.5±10.8  
Total 3,955 80.9±11.3  
Pulse 
(bpm) 
non PCOS 3,935 76.7±9.6 0.849 
PCOS 20 76.3±8.9  
Total 3,955 76.7±9.5  
Values are means ± standard deviation. Abbreviations: BMI, Body Mass Index 
†Significance level of the difference between PCOS and non PCOS groups at each time point, 
calculated using an independent t-test 
* marks the significant difference between the 2 groups, p < 0.05 
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Table 26: Baseline characteristics in the Caucasian Subgroup between the PCOS 
and non PCOS participants 
 
 
PCOS 
Category 
N Mean± SD P† 
Age (yrs) 
non PCOS 94,200 42.2±11.3 <0.001* 
PCOS 437 34.9±8.2  
Total 94,637 42.2±11.3  
Height (m) 
non PCOS 94,200 1.64±0.07 0.05* 
PCOS 437 1.65±0.07  
Total 94,637 1.64±0.07  
Weight 
(kg) 
non PCOS 94,200 98.0±16.9 <0.001* 
PCOS 437 106.3±19.1  
Total 94,637 98.1±17.0  
BMI 
(kg/m2) 
non PCOS 94,200 36.4±5.8 <0.001* 
PCOS 437 39.1±6.7  
Total 94,637 36.4±5.8  
Systolic BP 
(mmHg) 
non PCOS 93,595 129.2±15.1 0.068 
PCOS 434 128.0±12.4  
Total 94,029 129.3±15.1  
Diastolic 
BP 
(mmHg) 
non PCOS 93,595 81.2±10.5 0.521 
PCOS 434 81.5±10.2  
Total 94,029 81.2±10.5  
Pulse 
(bpm) 
non PCOS 93,595 75.8±9.3 0.158 
PCOS 434 76.4±8.7  
Total 94,029 75.8  
Values are means ± standard deviation. Abbreviations: BMI, Body Mass Index 
†Significance level of the difference between PCOS and non PCOS groups at each time point, 
calculated using an independent t-test 
* marks the significant difference between the 2 groups, p < 0.05 
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4.2 Comparison of participants with and without PCOS after 12 weeks 
on the LighterLife Total programme 
 
 
After the baseline investigation of the database, the PCOS participants were 
matched for age (age ±1 unit) and BMI (BMI ± 1 unit) with the non PCOS 
participants in order to proceed to the 12 week analysis. The 12 week part 
included both a Baseline Carried Forward analysis (BOCF) on the Intention to 
Treat sample (ITT) (n=508 for PCOS and n=508 for non PCOS) and a 
Completers (n=137 for PCOS and n=137 for non PCOS) analysis.  
 
4.2.1 BOCF Analysis 
 
 
There were no differences between the PCOS and non PCOS women in age (yrs) 
(34.5±8.2 versus 34.5±8.2, p=0.948), height (m) (1.65±0.1 versus 1.65±0.1, 
p=0.937), weight (kg)  (105.4±18.9 versus 105.3±19.0, p=0.892) and BMI 
(kg/m2)(38.9±6.4 versus 38.8±6.4, p=0.831), as they were all matched at 
baseline.  
 
The weekly weight loss as well as the weekly reduction in BMI, were similar for 
both groups, with no significant statistical differences (Table 27 and Table 28).  
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Table 27: Comparison of weekly weight between PCOS (n=508) and matched 
non PCOS individuals (n=508) 
 
Parameter Category Mean±SD P† 
Baseline Weight (kg) 
PCOS 105.4±18.9 0.831 
nonPCOS 105.3±19.0 
 
Week 1 Weight (kg) 
PCOS 102.2±18.4 0.884 
nonPCOS 102.0±18.4 
 
Week 2 Weight (kg) 
PCOS 100.7±18.2 0.831 
nonPCOS 100.4±18.4 
 
Week 3 Weight (kg) 
PCOS 99.6±18.4 0.783 
nonPCOS 99.3±18.4 
 
Week 4 Weight (kg) 
PCOS 98.7±18.4 0.790 
nonPCOS 98.3±18.3 
 
Week 5 Weight (kg) 
PCOS 97.7±18.3 0.808 
nonPCOS 97.4±18.3 
 
Week 6 Weight (kg) 
PCOS 96.9±18.4 0.846 
nonPCOS 96.7±18.4 
 
Week 7 Weight (kg) 
PCOS 96.2±18.5 0.832 
nonPCOS 96.0±18.7 
 
Week 8 Weight (kg) 
PCOS 95.9±18.6 0.691 
nonPCOS 95.5±18.9 
 
Week 9 Weight (kg) 
PCOS 95.5±18.7 0.699 
nonPCOS 95.0±19.1 
 
Week 10 Weight (kg) 
PCOS 95.1±18.7 0.790 
nonPCOS 94.8±19.2 
 
Week 11 Weight (kg) 
PCOS 95.1±18.8 0.660 
nonPCOS 94.6±19.4 
 
Week 12 Weight (kg) 
PCOS 95.0±19.1 0.927 
nonPCOS 94.9±19.5 
 
 
Values are means ± standard deviation. 
†Significance level of the difference between PCOS and non PCOS groups at each time point, 
calculated using an independent t-test 
* marks the significant difference between the 2 groups, p < 0.05,  
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Table 28: Comparison of weekly BMI between PCOS (n=508) and matched non 
PCOS individuals (n=508) 
 
Parameter Category Mean±SD P† 
Baseline BMI (kg/m2) 
PCOS 38.9±6.4 0.831 
nonPCOS 38.8±6.4 
 
Week 1 BMI (kg/m2) 
PCOS 37.7±6.3 0.816 
nonPCOS 37.6±6.2 
 
Week 2 BMI (kg/m2) 
PCOS 37.1±6.2 0.745 
nonPCOS 37.0±6.2 
 
Week 3 BMI (kg/m2) 
PCOS 36.7±6.3 0.714 
nonPCOS 36.6±6.2 
 
Week 4 BMI (kg/m2) 
PCOS 36.4±6.3 0.723 
nonPCOS 36.3±6.2 
 
Week 5 BMI (kg/m2) 
PCOS 36.0±6.3 0.751 
nonPCOS 35.9±6.2 
 
Week 6 BMI (kg/m2) 
PCOS 35.7±6.3 0.798 
nonPCOS 35.6±6.3 
 
Week 7 BMI (kg/m2) 
PCOS 35.5±6.4 0.774 
nonPCOS 35.4±6.4 
 
Week 8 BMI (kg/m2) 
PCOS 35.4±6.4 0.647 
nonPCOS 35.2±6.5 
 
Week 9 BMI (kg/m2) 
PCOS 35.2±6.4 0.651 
nonPCOS 35.0±6.6 
 
Week 10 BMI (kg/m2) 
PCOS 35.1±6.5 0.739 
nonPCOS 35.0±6.6 
 
Week 11 BMI (kg/m2) 
PCOS 35.1±6.5 0.614 
nonPCOS 34.9±6.7 
 
Week 12 BMI (kg/m2) 
PCOS 35.0±6.6 0.895 
nonPCOS 35.0±6.8 
 
 
Values are means ± standard deviation. Abbreviations: BMI, Body Mass Index 
†Significance level of the difference between PCOS and non PCOS groups at each time point, 
calculated using an independent t-test 
* marks the significant difference between the 2 groups, p < 0.05 
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After 12 weeks of VLCD, there was a significant weight reduction for both groups 
when compared to baseline (PCOS: 105.4kg ±18.9 versus 95.0 kg ±19.1 
p<0.001 and non-PCOS: 105.3kg ±19.0 versus 94.9kg ±19.5, p<0.001). There 
was also a significant change in BMI, as compared to baseline (PCOS: 38.9±6.4 
kg/m 2 versus 35.0±6.6 kg/m 2, p<0.001 and non-PCOS: 38.8±6.4 kg/m 2 versus 
35.0±6.8 kg/m 2, p<0.001). The total weight change did not differ significantly 
between the PCOS group and the non-PCOS group (-10.4kg ±10.6 versus -10.4 
kg ± 10.4, p=0.938) and both of the groups achieved approximately 10% 
weight loss after the 12 week VLCD approach (PCOS: -9.7%±9.4 vs non PCOS: -
9.7%±9.7, p=0.965. Moreover, no significant differences in the weekly weight 
change between the two groups were identified, as demonstrated at the 
following figure. 
 
 
Figure 4: Weekly weight change for participants with and without PCOS (12 week BOCF, n=508 
for each group), Error bars represent 1 SE 
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The tables below show the changes in systolic and diastolic blood pressure and 
pulse between the PCOS and non PCOS groups, after the 12 week period.  
 
 
Table 29: Comparison of blood pressure and pulse between the PCOS and non 
PCOS groups at baseline and at 12 weeks 
 
Parameter Category N Mean±SD P† 
Baseline Systolic BP (mmHg) PCOS 504 127.4±12.5 0.598 
nonPCOS 507 127.0±14.0  
Baseline Diastolic BP (mmHg) PCOS 504 81.5±10.2 0.014* 
nonPCOS 508 79.9±9.7  
Baseline Pulse (bpm) PCOS 504 76.5±9.0 0.694 
nonPCOS 506 76.3±9.2  
Week12 Systolic BP (mmHg) PCOS 504 121.9±20.3  <0.001* 
nonPCOS 507 126.1±14.5  
Week12 Diastolic BP (mmHg) PCOS 504 85.8±16.1 0.206 
nonPCOS 508 79.4±9.9  
Week12 Pulse (bpm) PCOS 504 76.1±9.3 0.817 
nonPCOS 506 76.0±9.2  
Values are means ± standard deviation.  
†Significance level of the difference between PCOS and non PCOS groups, calculated using an independent t-
test 
* marks the significant difference between the 2 groups, p < 0.05, calculated using an independent t-test 
Week 12 Diastolic BP was adjusted for baseline difference using analysis of covariance (ANCOVA) 
 
 
 
Table 30: Comparison of changes in blood pressure between the PCOS and non 
PCOS groups after 12 weeks of VLCD 
 
Parameter Category N Mean±SD P† 
Change in Syst 
BP (mmHg) 
nonPCOS 507 -5.5±6.1 <0.001* 
PCOS 504 -0.9±6.1  
Change in Diast 
BP (mmHg) 
nonPCOS 507 -0.4±5.1 0.517 
PCOS 504 -0.6±4.4  
Values are means ± standard deviation.  
†Significance level of the difference between PCOS and non PCOS groups, calculated using an independent t-
test 
* marks the significant difference between the 2 groups, p < 0.05, calculated using an independent t-test 
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Finally, the distribution of the ethnic categories was also similar between the 2 
groups of participants (figure 5 and 6), although the numbers of some minority 
groups differed. However, due to the small numbers in some of the ethnic 
groups, comparisons between the different ethnic categories could not be 
performed. 
 
 
 
Figure 5: The different ethnic groups among the non PCOS (n=508) 12 week BOCF 
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Figure 6: The different ethnic groups among the PCOS (n=508) 12 week BOCF 
 
 
 
A combined analysis of the distribution of ethnic categories, showed greater 
proportion of Asians in the PCOS category (Table 31).  
 
 
 
Table 31: Combined Ethnicities in the PCOS and non PCOS group 
 
 
Combined Ethnicities 
 
Non PCOS (%) 
 
 
PCOS (%) 
 
Total 
Caucasian 459 (90.4%) 431 (84.8 %) 890 
Asian 30 (5.9%) 57 (11.2 %) 87 
African 19 (3.7%) 20 (3.9%) 39 
Total 508 508 1016 
 
(chi Square Value 0.010) 
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4.2.2 Completers analysis 
 
As it can be seen from the following table, there were no differences between 
the PCOS and non PCOS women in age (yrs) (35.7±8.9 versus 35.8±8.9, 
p=0.946), height (m)  (1.65±0.1 versus 1.64±0.1, p=0.212), weight (kg) 
(108.3±18.1 versus 107.4±19.8, p=0.713) and BMI (kg/m2)(40.0±6.3 versus 
40.0±6.3, p=0.955).  
 
Table 32: Comparison of baseline characteristics between PCOS (n=137)  
and matched non PCOS (n=137) 
 
Parameter non PCOS (n=137) PCOS (n=137) P† 
Age (yrs) 35.8±8.9 35.7±8.9 0.946 
Height (m) 1.64±0.1 1.65±0.1 0.212 
Weight (kg) 107.4±19.8 108.3±18.1 0.713 
BMI (kg/m2) 40.0±6.3 40.0±6.3 0.955 
 
Values are means ± standard deviation. Abbreviations: BMI, Body Mass Index 
†Significance level of the difference between PCOS and non PCOS groups at baseline,  
calculated using an independent t-test 
 
The weekly weight loss as well as the weekly reduction in BMI, were similar for 
both groups, with no significant statistical differences (Table 33 and Table 34).  
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Table 33: Comparison of weekly weight (kg) between PCOS (n=137) and 
matched non PCOS (n=137) individuals 
 
Parameter Category Mean±SD P† 
Baseline Weight 
(kg) 
nonPCOS 107.4±19.8 0.713 
PCOS 108.3±18.1  
Week 1 Weight (kg) 
nonPCOS 104.1±19.3 0.917 
PCOS 103.8±19.9  
Week 2 Weight (kg) 
nonPCOS 103.4±26.3 0.724 
PCOS 102.4±17.4  
Week 3 Weight (kg) 
nonPCOS 100.2±18.7 0.887 
PCOS 99.8±19.0  
Week 4 Weight (kg) 
nonPCOS 98.6±18.5 0.748 
PCOS 97.9±19.7  
Week 5 Weight (kg) 
nonPCOS 97.0±18.3 0.956 
PCOS 96.9±18.6  
Week 6 Weight (kg) 
nonPCOS 95.4±18.3 0.619 
PCOS 96.5±16.7  
Week 7 Weight (kg) 
nonPCOS 94.1±18.2 0.602 
PCOS 95.2±16.7  
Week 8 Weight (kg) 
nonPCOS 92.7±17.9 0.515 
PCOS 94.1±16.7  
Week 9 Weight (kg) 
nonPCOS 91.4±17.9 0.436 
PCOS 93.0±17.0  
Week 10 Weight 
(kg) 
nonPCOS 90.2±17.8 0.600 
PCOS 91.4±17.4  
Week 11 Weight 
(kg) 
nonPCOS 89.3±17.9 0.731 
PCOS 90.1±18.2  
Week 12 Weight 
(kg) 
nonPCOS 88.0±17.6 0.381 
PCOS 89.8±16.7  
 
Values are means ± standard deviation.  
†Significance level of the difference between PCOS and non PCOS groups at each time point, 
calculated using an independent t-test 
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Table 34: Comparison of weekly BMI (kg/m2) between PCOS (n=137) and 
matched non PCOS (n=137) individuals 
 
Parameter Category Mean±SD P† 
Baseline BMI 
(kg/m2) 
nonPCOS 40.0±6.3 0.955 
PCOS 40.0±6.3  
Week 1 BMI 
(kg/m2) 
nonPCOS 38.8±6.2 0.604 
PCOS 38.4±7.1  
Week 2 BMI 
(kg/m2) 
nonPCOS 38.5±9.2 0.461 
PCOS 37.8±6.1  
Week 3 BMI 
(kg/m2) 
nonPCOS 37.3±6.0 0.522 
PCOS 36.8±6.7  
Week 4 BMI 
(kg/m2) 
nonPCOS 36.7±6.0 0.407 
PCOS 36.1±7.0  
Week 5 BMI 
(kg/m2) 
nonPCOS 36.2±5.9 0.597 
PCOS 35.8±6.6  
Week 6 BMI 
(kg/m2) 
nonPCOS 35.5±5.9 0.900 
PCOS 35.6±5.9  
Week 7 BMI 
(kg/m2) 
nonPCOS 35.1±5.8 0.870 
PCOS 35.2±6.0  
Week 8 BMI 
(kg/m2) 
nonPCOS 34.5±5.7 0.756 
PCOS 34.7±6.0  
Week 9 BMI 
(kg/m2) 
nonPCOS 34.0±5.8 0.652 
PCOS 34.3±6.0  
Week 10 BMI 
(kg/m2) 
nonPCOS 33.6±5.7 0.859 
PCOS 33.7±6.2  
Week 11 BMI 
(kg/m2) 
nonPCOS 33.3±5.7 0.991 
PCOS 33.2±6.5  
Week 12 BMI 
(kg/m2) 
nonPCOS 32.8±5.7 0.568 
PCOS 33.2±6.0  
 
Values are means ± standard deviation. Abbreviations: BMI, Body Mass Index 
†Significance level of the difference between PCOS and non PCOS groups at each time point, 
calculated using an independent t-test 
 
 
After 12 weeks of VLCD, there was a significant weight reduction for both groups 
when compared to baseline (PCOS: 108.3 kg ±18.1 versus 89.8 kg ±16.7, 
p<0.001 and non-PCOS: 107.4 kg ±19.8 versus 88.0 kg ± 17.6, p<0.001). 
There was also a significant change in BMI, as compared to baseline (PCOS: 
40.0±6.4 kg/m 2 versus 33.2±6.0 kg/m 2, p<0.001 and non-PCOS: 40.0±6.3 
kg/m 2 versus 32.8±5.7 kg/m 2, p<0.001). The total weight change did not differ 
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significantly between the PCOS group and the non-PCOS group (-18.5 kg ±6.6 
versus -19.4 kg± 5.7, p=0.190) and the percentage of weight loss achieved by 
PCOS women was 17.1% ±5.6 versus 18.2% ±4.4 by the non PCOS group 
(p=0.08). Moreover, no significant differences in the weekly weight change 
between the two groups were identified. 
 
 
Figure 7: Weekly weight change for participants with and without PCOS (12 week completers, 
n=137 for each group), Error bars represent 1 SE 
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As there were not enough data to examine changes in waist, hip and bust, the 
next table shows the BP values at baseline and after 12 weeks of VLCD. 
 
 
Table 35: Values on blood pressure and pulse between the PCOS and non PCOS 
groups at baseline and 12 weeks 
 
Parameter Category N Mean±SD P† 
Baseline Systolic  
(mmHg) 
nonPCOS 137 130.5±13.9 0.014* 
PCOS 137 127.2±12.4  
Baseline Diastolic 
 (mmHg) 
nonPCOS 137 80.5±9.6 0.598 
PCOS 137 81.3±9.8  
Baseline Pulse  
(bpm) 
nonPCOS 137 75.9±9.1 0.694 
PCOS 504 76.7±8.9  
Week 12 Systolic BP 
(mmHg) 
nonPCOS 49 119.4±13.8 0.8 
PCOS 57 119.1±13.6  
Week 12 Diastolic BP 
(mmHg) 
nonPCOS 49 74.9±10.2 0.237 
PCOS 57 77.5 ±11.6  
Week 12 Pulse BP  
(bpm) 
nonPCOS 49 72.9±8.8 0.823 
PCOS 57 72.4±10.2  
Values are means ± standard deviation. 
†Significance level of the difference between PCOS and non PCOS groups, calculated using an independent t-
test 
* marks the significant difference between the 2 groups at baseline, p < 0.05, calculated using an independent 
t-test 
 
 
Table 36: Comparison of changes in blood pressure between the PCOS and non 
PCOS groups after 12 weeks of VLCD 
 
 
Parameter Category N Mean±SD P† 
Change in Systolic BP PCOS 57 -6.8±17.1 0.567 
 non PCOS 49 -8.7±17.1  
Change in Diastolic BP PCOS 57 -3.9±12.7 0.455 
 non PCOS 49 -5.6±12.8  
 
 
 
Finally, the distribution of the ethnic categories was similar between the 2 
groups of participants (figure 8 and 9), although the numbers of some minority 
groups differed. However, due to the small numbers in some of the ethnic 
groups, comparisons between the different ethnic categories could not be 
performed. 
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Figure 8: The different ethnic groups among the non PCOS (n=137) 12 week completers 
 
 
 
 
 
 
Figure 9: The different ethnic groups among the PCOS (n=137) 12 week completers 
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4.3 Part 3: Comparison of participants with and without PCOS 1 year 
after commencing the Lighter Life Total programme 
 
4.3.1 1 year data from the participants who finished the 12 week 
programme 
 
 
From the 274 participants who completed the 12 week programme, 1 year data 
were only available for 35 in the non PCOS category and 41 in the PCOS 
category. The following table shows that there were no differences between the 
PCOS and non PCOS women at baseline. 
 
Table 37: Comparison of baseline and 1 year characteristics between PCOS (n=41) and  
non PCOS (n=35) individuals 
Parameter Category N Mean±SD P† 
Age (yrs) 
nonPCOS 35 35.7±8.9 0.946 
PCOS 41 35.8±8.9 
 
Height (m) 
nonPCOS 35 1.65±0.1 0.212 
PCOS 41 1.64±0.1 
 
Baseline Weight (kg) 
nonPCOS 35 107.4±19.8 0.713 
PCOS 41 108.3±18.1 
 
Baseline BMI (kg/m2) 
nonPCOS 35 40.0±6.3 0.955 
PCOS 41 40.0±6.3 
 
Y1 Weight (kg) 
nonPCOS 35 90.27±27.6 0.476 
PCOS 41 94.18±19.9 
 
Y1 BMI (kg/m2) 
nonPCOS 35 33.37±8.5 0.335 
PCOS 41 35.16±7.6 
 
 
Values are means ± standard deviation. 
†Significance level of the difference between PCOS and non PCOS groups, calculated using an independent t-
test 
* marks the significant difference between the 2 groups at baseline, p < 0.05, calculated using an independent 
t-test 
 
Even after a year, the weight was significant lower than baseline for both groups 
(PCOS: 108.3kg ±18.1 versus 94.2kg ±19.9, p<0.001 and non-PCOS: 107.4 kg 
±19.8 versus 90.3±27.6, p<0.001). Similarly, BMI remained lower as compared 
to baseline (PCOS: 40.0±6.3 versus 35.2±7.6 kg/m2, p<0.001 and non-PCOS: 
40.06±6. kg/m 2 versus, 33.4±8.5kg/m2, p<0.001). Moreover, the total weight 
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change did not differ significantly between the PCOS and the non-PCOS group ( -
18.9 kg ± 6.6 versus -20.4kg ±5.3, p=0.271) at 1 year, as it can be seen from 
the following figures. Moreover, the percentage of weight loss achieved by PCOS 
women at 1 year was similar with the one achieved by the non PCOS women (-
15.6%±15.6 versus -12.4% ± 13.3, p=0.35).  
 
 
 
 
Figure 10: Comparison of weight at baseline, week 12 and 1 year between PCOS and PCOS 
(completers), Error bars 1represent 1 SE  
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Figure 11: Comparison of BMI (kg/m2) at baseline, week 12 and 1 year between PCOS and PCOS 
(completers), Error bars represent 1 SE 
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4.3.2 BOCF from the participants who finished the 12 week programme 
 
The following table shows that there were no differences between the PCOS and 
non PCOS women both at baseline and at 1 year.  
 
Table 38: Comparison of baseline and 1 year characteristics between PCOS (n=95) and  
non PCOS (n=103) individuals 
Parameter Category N Mean±SD P† 
Age (yrs) 
nonPCOS 103 35.2±7.8 0.271 
PCOS 95 36.5±8.1 
 
Height (m) 
nonPCOS 103 1.64±0.1 0.606 
PCOS 95 1.64±0.1 
 
Baseline Weight (kg) 
nonPCOS 103 101.4±18.1 0.404 
PCOS 95 103.6±18.0 
 
Baseline BMI (kg/m2) 
nonPCOS 103 37.5±5.7 0.176 
PCOS 95 38.7±6.7 
 
Y1 Weight(kg) 
nonPCOS 103 84.7±17.9 0.01* 
PCOS 95 91.4±18.9 
 
Y1 BMI (kg/m2) 
nonPCOS 103 31.3±5.8 0.002* 
PCOS 95 34.1±6.9 
 
 
Values are means ± standard deviation. 
†Significance level of the difference between PCOS and non PCOS groups, calculated using an independent t-
test 
* marks the significant difference between the 2 groups at baseline, p < 0.05, calculated using an independent 
t-test 
 
 
Even after a year, the weight was significant lower than baseline for both groups 
(PCOS: 91.5 kg ± 18.9 versus 103.6 kg ± 18.0, p<0.001 and non-PCOS: 84.7 
kg ± 17.9 versus 101.4 kg ±18.1 , p<0.001). Similarly, BMI remained lower as 
compared to baseline (PCOS: 34.1±6.9 kg/m2 versus 38.7± 6.7 kg/m2, p<0.001 
and non-PCOS: 31.3 ± 5.8 kg/m 2 versus, 37.5 ± 5.7 kg/m2, p<0.001). 
Moreover, the total weight change differ significantly between the PCOS and the 
non-PCOS group (-12.3 ±14.7 kg versus -16.7±14.4, p=0.032) at 1 year, as did 
the percentage of weight loss: PCOS 11.3% ±13.6 versus non PCOS 15.9 %± 
12.6, p=0.014. 
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Figure 12: Comparison of weight at baseline, week 12 and 1 year between PCOS and PCOS at the 
BOCF analysis, Error bars represent 1 SE 
 
 
 
Figure 13: Comparison of weight at baseline, week 12 and 1 year between PCOS and PCOS at the 
BOCF analysis, Error bars represent 1 SE 
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5. Discussion 
 
One of the major health problems nowadays is the increasing prevalence of 
obesity. According to the National Infertility Group Report (2013), half of the 
women of reproductive age are either overweight or obese. Increased weight, 
and in particular central obesity, plays an important role in the development of 
PCOS, thus the majority of women with this syndrome are either overweight or 
obese (Gambineri et al. 2002). Although the exact pathophysiological 
interactions between excess weight and the clinical expression of PCOS have not 
been deciphered yet, it is generally acknowledged that obesity itself is an 
independent factor associated with disturbances in the sex steroid metabolism 
(Pasquali et al. 2006), insulin resistance (Reaven et al. 1983) as well as in 
menstrual irregularities (Svendsen et al. 2008). Obesity in PCOS however, 
exacerbates the reproductive, metabolic and psychological effects of excessive 
weight, thus optimal dietary guidelines in the area of PCOS are of crucial 
importance. Despite the fact that the first line treatment is weight loss through 
lifestyle interventions, the complexity and the heterogeneity of this syndrome in 
conjunction with the lack of robust large scale randomised clinical trials, lead to 
lack of optimal dietary guidelines. This study, attempted to investigate the effect 
of a commercial VLCD programme in conjunction with behavioural change 
meetings, on weight loss in overweight and obese women with PCOS as 
compared to women without this syndrome. Although further investigations are 
needed, the results suggest that women with PCOS lose the same weight at 12 
weeks and maintain similar weight loss with the non PCOS group after 1 year. 
More details are discussed below. 
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5.1 Baseline Analysis 
 
The prevalence of PCOS among the LL clients that followed the Total approach 
between 2006 and 2011, was only 0.5%, a percentage much lower than the 
current estimates, which vary from 5 to 26% (Hopkinson 1998). For example, 
6.5% prevalence in unselected Caucasian population in Spain (Asuncion et al. 
2000), 8.0% among Black and 4.8% among Caucasian in United States (Azziz et 
al. 2004) while Knochenhauer et al. (1998) found 4.7% of Caucasian and 3.4% 
of Black  in United States. Volunteers were recruited from two universities and 
two general practice surgeries in Oxford. 230 women aged 18–25 years 
participated The prevalence of PCOS in this age group was as low as 8% or as 
high as 26% depending on which criteria were applied to define the syndrome. 
(Michelmore et al. 1999). However, as mentioned in the introduction, the studies 
that have estimated the prevalence of PCOS, not only were performed among 
different populations (e.g. Britain, Italy, Spain, USA) but also used different 
diagnostic criteria. Furthermore, due to the high costs of carrying out diagnostic 
tests in large populations, the results in the majority of the studies were based 
on convenience samples, usually less than 400 individuals (March et al. 2010). 
Consequently, the prevalence calculated in these studies could be biased as the 
population is comprised only by those who responded to the study 
advertisement. Regarding the database analysis included in this project, the 
sample gained was solely comprised of overweight and obese women, excluding 
any normal weight women with PCOS or overweight women with PCOS that 
followed any of the other approaches that LighterLife offers. Also, in the majority 
of the studies available in the literature, the age range of the sample is 
purposely limited to premenopausal women, whereas in this study the age range 
was wider (18-75 years), to represent all the age groups. Moreover, the 
prevalence of PCOS greatly depends on which criteria are used by the physicians 
to diagnose this syndrome. However, we are not aware of the criteria used for 
the diagnosis of the PCOS participants in the LL database. This can be attributed 
to the lack of notes regarding the diagnosis on the medical form and also to the 
fact that the medical practitioner who made the diagnosis could not be 
contacted. Another potential bias could be the financial status, as only women 
who can afford the weekly costs of this commercial programme (approximately 
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£80 per week) were included. Moreover, according to previous reports (Magnoti 
and Futterweit 2007, March et al. 2010) up to 69% of women with PCOS in the 
community may remain undiagnosed.  Furthermore, anecdotal evidence from 
NHS Information Services Division supports that many cases of PCOS (PCOS 
population in Scotland, is 0.1% for 2010/11), are classified under 
endocrinological or fertility disorders, a fact that influences the actual prevalence 
of this syndrome. 
 
During the database analysis, it was noted that the prevalence of PCOS was 
higher in Asians than in Caucasians (almost 3 times more), which is in 
accordance with a number of papers (Rodin et al.1998, Wijeyaratne et al. 2002, 
Eriksson et al. 2012). According to the literature, it has been observed that 
Asians are more predisposed to T2DM than Caucasians, which in connection with 
the strong link between decreased insulin sensitivity and PCOS, it could explain 
the higher prevalence of PCOS in Asians when compared to Caucasians 
(Wijeyaratne et al. 2011). Yet, some results are conflicting due to the limited 
research in this area (Crosignani and Nicolosi, 2001). In addition, the clinical 
presentation of PCOS may vary significantly between Caucasian and Asian 
populations due to the different genetic predispositions (Balen and Michelmore 
2002). For example, is quite common for women of Asian origin to have 
increased body hair (or at least more noticeable). 
 
The baseline analysis of the database revealed some significant differences in 
anthropometric and metabolic parameters between obese women with and 
without PCOS. Participants with PCOS were significantly younger than women 
without the syndrome, which could imply that many of them were prompted to 
search for a diagnosis after unsuccessful attempts to conceive, a fact that is in 
accordance with the literature. Another possible reason could be the influence of 
several socioeconomic factors, such as family environment and education 
received, which may have prompted them to ask for help at an earlier age.  
 
Furthermore, PCOS participants had a higher weight and BMI than non PCOS. 
However, it is still debatable whether heavier women are predisposed to PCOS or 
are obese because they have PCOS or the differences between women with and 
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without PCOS are more likely due to environmental and lifestyle factors (Hoeger 
and Oberfield 2012) 
 
Increased abdominal adiposity is another frequent characteristic among PCOS 
women (Barber et al. 2006, Kirchengast and Huber, 2001), even in cases of 
normal weight (Kirchengast and Huber 2001), although a small number of 
studies revealed no differences in body fat distribution between obese women 
with and without PCOS (Carmina et al. 2005). Moreover, in PCOS, central 
obesity per se, may play a crucial role in influencing the steroid metabolism as 
well as the insulin resistance. Initial results from the LL database showed that 
although the waist and hip circumference were higher in PCOS participants, the 
WHR did not differ significantly. However, the results may be biased, as 
measuring waist and hip girths in obese individuals, increases the risk for 
technical errors (Stewart et al. 2010). Also, larger bust circumference was 
observed in PCOS women, which could be attributed either to their higher BMI or 
to the frequent use of oral contraceptives, which is a common medication among 
women with PCOS, as it induces regular menstruation (Eriksson et al. 2012, 
Jernstrom and Olsson 1997).  
 
Pulse and diastolic blood pressure did not differ between women with and 
without PCOS, however, PCOS women had lower levels of systolic blood 
pressure, despite the fact that they were heavier and literature has shown that 
PCOS may predispose towards hypertension (Chen et al. 2007). The lower 
values observed, could be attributed to the fact that PCOS women were younger 
or depict that they receive regular medication to control their pressure (52 
women with PCOS receive antihypertensive medication versus 16 non PCOS). 
 
5.2 12 weeks and 1 year analysis 
 
It is generally proposed that as little as 5% weight loss can improve fertility 
outcomes. In this study, PCOS (completers) achieved similar weight reduction 
with the non PCOS (completers) group: was 17.1% ±5.6 (PCOS completers) 
versus 18.2% ±4.4 by the non PCOS group (p=0.08). after 12 weeks of VLCD in 
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conjunction with group counselling. The ITT analysis (for the participants that 
started the 12 week programme but did not complete it), showed more 
conservative results, due to fact that the BOCF method was used (10% weight 
loss for both PCOS and non PCOS participants), however both of the groups 
achieved approximately 10% weight loss after the 12 week VLCD approach 
(PCOS: -9.7%±9.4 vs non PCOS: -9.7%±9.7, p=0.965. Interestingly, at 1 year, 
a weight loss of 12.4% was still maintained for the PCOS individuals versus 
15.6% for the non PCOS group, p=0.35.  
 
These results are intriguing because a number of papers have mentioned that 
women with PCOS may face difficulties in achieving weight loss due to some 
metabolic issues, however none of them tested the response of women with 
PCOS to a VLCD with an incorporated behavioural component. More specifically, 
PCOS patients may have reduced postprandial thermogenesis associated with 
reduced insulin sensitivity (Robinson et al. 1992). Moreover, adjusted basal 
metabolic rate (BMR) appears to be statistically significantly lower in women 
with PCOS, and is more evident in women with both PCOS and insulin resistance 
(Georgopoulos et al. 2009).  
 
Furthermore, after diet-induced weight loss, due to a number of compensatory 
changes, weight regain may be stimulated. For example, the postprandial 
excretion of cholecystokinin (CCK), a hormone which increases satiety, appears 
to be significantly reduced after weight reduction in previously obese patients. 
Moreover, PCOS patients very often have deranged appetite regulation due to 
reduced postprandial CCK secretion, when compared to control age and BMI 
matched individuals without PCOS (Hirschberg et al. 2004). However, in cases 
where the weight reduction was achieved via a ketogenic diet –a high protein, 
high fat, low carbohydrate plan-, the levels of CCK maintained at similar 
concentrations with the ones before the weight loss (Chearskul et al. 2008). This 
could suggest that due to the anorexogenic effect of ketosis, the levels of CCK 
were normalised among the PCOS patients and similar weight loss was achieved 
when compared to the non PCOS group.  
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5.3 Strengths and Limitations 
 
Although the gold standard in evaluating healthcare interventions are carefully 
designed, conducted and reported randomised controlled trials, due to time 
limitations and financial restraints, the utilisation of the extensive LighterLife 
database was the most appropriate method for this project. These population-
based retrospective analyses, assessed the effectiveness of a commercial VLCD 
in conjunction with weekly counselling group sessions, as it runs for real clients 
who joined the programme to achieve weight reduction. This can be seen as a 
strength, because the results depict a snapshot of the PCOS community. Also, 
due to the fact that the population of the database was drawn from several 
geographic areas around the UK, any socioeconomical biases associated with 
sample selection were minimised. However, deprived areas may have not been 
represented in this analysis, as participation on this commercial programme 
requires a good financial status. 
 
The main strength of the current study is that this is the largest investigation to 
date, of the effect of a commercial VLCD in conjunction with a behavioural 
component, on obese women with PCOS as compared to obese women without 
this syndrome. Its findings suggest that women with PCOS lose the same 
amount of weight and at the same rate as non-PCOS women, after following a 
commercial VLCD programme for 12 weeks, and that at least 13% weight loss is 
maintained at 1 year follow up. Although mainly based on anecdotal evidence, 
there is the wide perception that overweight and obese women with PCOS find it 
harder to lose weight when compared to women without this condition, either 
due to underlying physiological mechanisms that could influence the energy 
expenditure e .g reduced postprandial thermogenesis in PCOS (Robinson et al. 
1992) or due to the emotional distress that accompanies this disorder, and 
predisposes towards increased energy consumption. 
 
While improvements in weight and BMI have been reported by other studies 
using variable dietary approaches, these studies lacked a control group (Moran 
et al. 2003; Moran et al. 2006; Stamets et al. 2004) whereas in the present 
study, women without PCOS acted as the control group and were also matched 
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for age and BMI for further analysis. Moreover, this is the only study in the area 
of PCOS and VLCDs that incorporates the counselling component, although the 
effect of counselling per se was not assessed. However, it is known that the 
element of the behavioural change, not only can enhance weight loss but may 
also improve the completion rates of weight loss programmes (Brown et al. 
2004). This support is of extreme importance among PCOS patients, where 
higher incidences of depressive and anxiety disorders may predispose them 
towards unhealthy eating behaviours.  
 
However, a number of limitations were encountered throughout the analysis, 
mainly associated with either the retrospective design of this research or with 
the lack of data in some cases.  
 
Firstly, there is no information on the criteria used for diagnosis of the PCOS 
status and it is highly possible that each of the PCOS women have been 
diagnosed by a different doctor. It is also probable that some women in the non 
PCOS group may have remained undiagnosed. This could impact not only in 
underestimating the prevalence of PCOS in this sample but could also influence 
the differences between the PCOS and non PCOS group (they could be less 
prominent). Moreover, due to the small numbers encountered in some of the 
ethnic groups, comparisons between the different ethnic categories encountered, 
could not be performed. However, wherever appropriate, some smaller groups 
were combined into larger groups e.g. Indians, Bangladeshis and Pakistanis were 
combined under the category of Asians. 
 
In addition, it was initially planned that the medications would be categorised 
into Defined Daily Doses as this is the “assumed average maintenance dose per 
day for a drug used for its main indication in adults” (WHO 2009). However, 
information on the dosage was not always available and in some cases instead of 
the name of the medication or the active compound, the description of the 
health issue was provided. Moreover, the medication list was not updated after 
the 28day checkups, and a history of the medication consumption by the 
participants throughout the VLCD was provided instead. Thus, changing the 
prescription as a result of weight loss  (e.g. Metformin) could not be assessed.  
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Furthermore, a number of measurements regarding waist, hip and bust 
circumferences as well as systolic and diastolic blood pressure and pulse were 
missing, a fact that may have influenced the findings of this project. Although 
for the 12 week data the analyses were performed for all the available values, 
for the 12 month data only weight and attendance rates were available.  
 
Moreover, the attendance rates were not always provided and in some cases the 
numbers given could imply either the attendance of the counselling session or 
just the visit of the individual in order to get the weekly supply of foodpacks or 
both. Also, the total numbers of weeks on weight loss or management (food re-
introduction programme after the VLCD) were not always mentioned in the 
database. 
 
In addition, although the LighterLife Counsellors are trained to perform the 
anthropometric measurements via standardised techniques, it is possible that a 
number of interobserver and intraobserver errors may have occurred, which may 
have lead to overestimation or underestimation of some measurements. 
Furthermore, although the facilitators have been trained to run the counselling 
sessions according to protocols based on CBT and TA, the individual approach 
and experience of each counsellor may influence the attendance and the long 
term efficacy of the program. 
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5.4 Conclusion 
 
PCOS is a complex condition, with diverse implications which include 
reproductive, metabolic and psychological comorbidities. Its clinical management 
should focus on lifestyle changes with medical therapy when required, as well as 
providing patients with support and education. Moreover, a VLCD in conjunction 
with behavioural changing sessions and nutritional counselling for food 
reintroduction, can comprise an effective way of weight loss among women with 
PCOS. However, evidence-based guidelines are still needed to guide clinicians 
and patients in optimummanagement of this syndrome.  
 
The present retrospective analysis suggests that women with PCOS lose the 
same amount of weight and at the same rate as non-PCOS women, after 
following a commercial VLCD programme for 12 weeks, in conjunction with 
group counselling sessions. Moreover, the weight maintenance at 12 months is 
similar for both the PCOS and non PCOS participants. Consequently, this 
approach could be used as an effective alternative to standard low calorie diets, 
especially in cases where difficulties in achieving weight loss are encountered. 
 
5.5 Future Research Implications 
 
There are several suggestions for further research in the area of PCOS. Firstly, 
the aetiology of PCOS as well as the interaction between genes, obesity, 
androgens and insulin resistance into the development of PCOS requires further 
research, including both laboratory studies and human trials.  
Secondly, the prevalence of PCOS in the UK should be estimated via the use of 
the same criteria. Moreover, a consensus over a global definition of PCOS should 
be reached, to assist future studies. It would also be useful to compare the 
prevalence and presentation of the syndrome among different ethnicities. For 
example, Asian women would be an interesting group to be targeted due to the 
greater prevalence of PCOS. 
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Thirdly, well planned long-term randomised controlled clinical trials with at least 
1 year follow up -and if possible to follow up until live births are achieved- are 
required. Also, comparison of the efficacy of the VLCD in conjunction with and 
without counselling -and other forms of behavioural therapy - in PCOS versus 
non PCOS, in age and BMI matched sample would be very interesting to be 
performed.  
 
Fourthly, further investigations are needed to investigate the metabolic rate and 
the postprandial thermogenesis in well designed studies comparing PCOS 
patients with age and BMI matched non-PCOS participants.  
 
Fifthly, data on the aetiology of PCOS as well as the hormone regulation of 
appetite and satiety in PCOS overweight/obese patients, require further 
investigation, so studies with greater sample size are needed.  
 
Sixthly, qualitative analysis investigating the personal experiences of weight loss 
among women with PCOS has not been conducted yet. Interviews or focus 
groups could be used to identify the spectrum of barriers that women with PCOS 
face while trying to lose weight. 
 
Last, the concept of triangulation could be used to add more insight into the 
subject of weight loss in overweight/obese women with PCOS. According to this 
concept, quantitative and qualitative methods can be combined to supplement 
and complement each other and offer a pluralistic methodological approach 
(Bryman, 2001). This method will provide a more complete way of fulfilling the 
research aim, by generating meaningful information that may have not been 
discovered with the sole use of one approach.  For example, the quantitative 
data can prove whether one dietary approach was successful or not (objective 
reality) whereas the qualitative approach will explain in depth this success or 
failure from an individual’s/group’s point of view (intersubjective reality). 
Moreover, this could lead to the generation of new hypotheses which could be 
tested through carefully designed clinical trials. 
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5.6 Recommendations for LighterLife Database Practice 
 
Due to the retrospective nature of this project and the problems encountered, 
the following recommendations could be implemented for a better practice in the 
future:  
 
Firstly, it would be useful for the counsellors to document for all their clients, 
who is attending each of the weekly behavioural sessions offered, as the 
behavioural therapy could possible enhance the weight loss and contribute to 
longer term weight maintenance.  
 
Secondly, synoptic tables with clear distinction between weeks of weight loss 
and management phase for each of the participants would be helpful.  
 
 
Moreover, changes in medication prescription and dosages should be recorded, 
to assess the effect of weight loss on medication.  
 
Last, the LL counsellors could improve their record keeping strategies e.g. 
electronic files instead of handwriting practice, to minimise loss of data.  
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